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Abstract
Dupuytren’s Disease (DD) is a benign and heritable connective tissue fibrosis that affects
the palmar fascia and typically results in permanent finger contracture(s). Similar to other
fibroses, DD is characterized by increased fibroblast proliferation, myofibroblast
differentiation and excess collagen deposition. Currently, there are no truly effective
treatment options for connective tissue fibroses.
Increased levels of β-catenin, an intracellular trans-regulator of gene transcription, have
been previously reported in DD. Genes that are associated with, and therefore potentially
transcriptionally regulated by, β-catenin during DD development were identified in this
thesis. One of these gene targets, IGFBP6, was shown to consistently be associated with
β-catenin in fibroblasts derived from phenotypically normal palmar fascia (PF cells) but
not fibroblasts derived from diseased tissues (DD cells). β-catenin association with the
IGFBP6 promoter in these cells was directly correlated with IGFBP6 expression levels
and with the secretion of its protein product, Insulin-like Growth Factor Binding Protein6 (IGFBP-6). In addition, 1438 unique genes were shown to associate with β-catenin in
DD cells but not PF cells derived from the same patients.
The functional consequences of IGFBP-6 repression, and the increased availability of its
primary ligand, IGF-II were also elucidated. Exogenous addition of IGFBP-6 attenuated
the proliferation of DD and control fibroblasts, and inhibited IGF-II induced contraction
of DD cells. IGF-II stimulated the proliferation of normal fibroblasts but not fibroblasts
derived from patients with DD. The gene encoding IGF-II, IGF2, was found to be up
regulated in DD cells, and potential mechanisms facilitating IGF2 overexpression were
investigated. Loss of imprinted expression of IGF2 was detected in a subset of patients
and a corresponding loss of H19 expression, a non-coding RNA that is reciprocally
expressed relative to IGF2, was observed. Aberrant IGF2 promoter usage was also
identified in a subset of DD and PF cells. In combination, these disease-associated
changes may explain the increased IGF2 expression in DD. Identification of novel gene
targets of β-catenin and the factors that regulate the expression of IGFBP6 or IGF2
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during the development of this debilitating fibrosis may allow us to identify novel
therapeutic targets.

Keywords
Dupuytren’s Disease, IGFBP-6, β-catenin, IGF-II, Fibrosis, Fibroproliferation,
Myofibroblast differentiation, ChIP Sequencing, Loss of Imprinting, IGF2 Promoter
Usage
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Chapter 1

1

General Introduction
1.1

Connective Tissue

The tissues of the human body can be divided into the four broad categories of nervous,
epithelial, muscle, and connective tissues [1,2]. Of these, connective tissues are the most
abundant and widely distributed, and they have essential structural and supportive
functions to hold and connect the other tissues of the body together. Connective tissue
itself can be subdivided into the four main classes of blood, bone, cartilage and
connective tissue proper [2,3], the latter encompassing loose (e.g. adipose, areolar,
reticular) and dense (e.g. regular, irregular and elastic) tissues [2].
Many connective tissues can be envisaged as relatively small numbers of cells embedded
in a “sea” of extracellular matrix (ECM). While the constituents of the ECM vary
considerably between the different classes, most consist of various fibres and components
of “ground substance”, such as proteoglycans and hyaluronic acid, that allow these
tissues to maintain a high water content [2]. The fibres secreted by connective tissue cells
include collagens, reticular and elastic fibres [1–3]. While many different cell types make
up the different classes of connective tissue, connective tissue proper is primarily
populated by fibroblasts [3]. This poorly characterized and heterogeneous group of
pleomorphic cells are of mesenchymal origin [3,4] and play central roles in secreting the
ground substance, fibres and many other molecules that make up the ECM of these
tissues [2,3,5].

1.2

Fibrosis

The term “fibrosis” refers to a disease state of connective or other tissues that is
characterized by abnormal remodelling of the ECM, which results in thickening and
hardening of tissues [6]. Major organ fibroses, such as those of the kidney [7], liver [8],
lungs [9,10], and heart [11] can result in catastrophic organ failure and death. Fibrosis has
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a significant etiological role in nearly 45% of deaths in the Western world that are the
result of loss of major organ function [12].
While the majority of connective tissue fibroses are not life threatening, they often cause
long term and debilitating loss of function of the affected area(s) and decreased quality of
life [13,14]. Fibroses can have variable etiologies and characteristics that are dependent
on the affected tissues, however many similarities between different fibroses exist at the
basic cellular and molecular levels. These similarities include increased Transforming
Growth Factor (TGF)-β1 signalling, excessive fibroproliferation, collagen deposition into
the ECM, and the formation and persistence of contractile myofibroblasts that contract
and remodel the ECM to increase tissue density [6,15–19].
The primary effector cell type in virtually all fibroses is the myofibroblast [17,20–22].
This cell type was initially characterized in granulation tissue as an “activated”
contractile form of dermal fibroblast that expresses α-smooth muscle actin (α-SMA)
within stress fibres [17,23–25]. Stress fibres allow myofibroblasts to generate the
contractile forces required to induce wound closure and tissue contraction [23]. These
fibroblasts can be resident in, or derived from tissues adjacent to, any tissue undergoing
fibrosis and their differentiation into myofibroblasts is central to fibrosis development
[20]. The conversion from fibroblast to myofibroblast can be initiated by changes in
mechanical tension, various growth factors such as TGF-β1, or a combination of these
factors [23–25]. Generally, highly proliferative fibroblasts do not express α-SMA or have
abundant stress fibres, whereas myofibroblasts invariably display α-SMA positive stress
fibres and often display a reduced proliferative potential [26]. There is an intermediate
form between the fibroblast and myofibroblast, the “protomyofibroblast”, that is thought
to retain the enhanced proliferative potential of a fibroblast, express cytoplasmic β and γ,
but not α-smooth muscle, actins in their stress fibres, and can generate an intermediate
level of contractile force on the ECM [27,28]. However, fully differentiated
myofibroblasts are the major source of the excessive collagen deposition, ECM
contraction and remodelling that are causal for the development of the dense collagenous
tissue that characterizes fibroses [27]. Under non-pathological circumstances,
myofibroblasts undergo apoptosis once wound contraction has been achieved. In fibroses,
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hyper-contractile, collagen-depositing myofibroblasts can persist for months or years
[29], and can continually activate ECM-associated latent TGF-β1 through a tensiondependent mechanism [30]. As TGF-β1 signalling can inhibit myofibroblast apoptosis
[31], these factors can act in combination to promote further fibrosis development.

1.3

TGF-β1 activation and signalling

TGF-β1 signalling is considered to be central to the development of virtually all fibroses
[20] as it can induce the production of α-SMA-containing stress fibres and enhanced
cellular contractility of myofibroblasts [23,32,33]. This cytokine is synthesized in an
inactive (latent) form and must first be activated to signal through its cognate receptors
[34,35]. Disulfide-linked dimers of Latency Associated Peptide (LAP) and TGF-β1
associate non-covalently to form the small latent complex, and if Latent TGF-β Binding
Protein (LTBP) is present in the ECM, it covalently binds LAP through two disulfide
bonds to form the large latent complex [34]. Active TGF-β1 can be released from this
complex by the actions of proteases [36] and, in the context of myofibroblast contraction,
increased tension or tissue stiffness through integrin binding to ECM-associated LAP
[30].
Once TGF-β1 has been released from the small- or large latent complex, it can transduce
signals from the ECM. TGF-β1 signals through two membrane associated receptors,
TGF-β Receptors I and II, to activate canonical SMAD (Sma/MAD) signalling [37,38].
The receptor-associated SMADs, SMAD2 and 3, are phosphorylated by receptor
activation and form a complex with SMAD4, allowing SMAD2 and SMAD3 to enter the
nucleus and elicit effects on the transcription of target genes that feature SMAD binding
elements, or they can interact with other transcription factors and trans-regulate gene
expression [37–40]. TGF-β1 can also initiate many parallel downstream pathways which
are not dependent on SMAD phosphorylation, such as the MAP kinase pathway [41].

1.4

Other pathways that cross-talk with TGF-β1

TGF-β1 signalling can induce diverse and, in some cell types, mutually exclusive
outcomes that include fibroblast proliferation and myofibroblast differentiation. For
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example, combined epidermal growth factor and TGF-β1 signalling can induce normal,
quiescent murine fibroblasts to proliferate faster than either factor in isolation, while
Insulin-like Growth Factor (IGF)-II and TGF-β1 signalling can induce the same
fibroblast cell line to become non-proliferative and take on features of contractile
myofibroblasts [42]. Both TGF-β1 and IGF signalling can induce β-catenin accumulation
in cells, and this intracellular signalling molecule can induce fibroblast proliferation or
migration [43–47]. As increased myofibroblast differentiation and fibroblast proliferation
are characteristics of all fibroses, and TGF-β1 signalling can have direct or indirect roles
in promoting these effects, many groups have attempted to target this cytokine to prevent
fibrosis development [11,48,49]. Unfortunately, TGF-β1 has integral and essential roles
in normal wound healing and the inflammatory response [50–52], which greatly
complicates its usefulness for therapeutic interventions. More recently, researchers have
opted for identifying and targeting molecules that are downstream of TGF-β1 signalling
or activate parallel signalling pathways that cross-talk with TGF-β1 signalling, to
promote pathological rather than normal tissue repair [53]. Further insights into the
molecular mechanisms that drive fibrosis development are required in order to identify
optimal targets for these approaches.

1.5

Dupuytren’s Disease

Our laboratory has focused on identifying these targets in Dupuytren’s Disease (DD). DD
is a fibrosis of the palmar fascia, which is a thin layer of connective tissue below the skin
in the palm of the hand. Like virtually all fibroses [15,21,54,55], DD is characterized by
increased TGF-β1 signalling, fibroblast proliferation, myofibroblast differentiation and
excess collagen deposition [56–59]. Patients with DD usually present to the clinic with
permanent and irreversible finger contractures [60–62]. Clinically, this disease is initially
evident as a nodule in the palm of the hand [63] consisting of proliferating myofibroblasts
[64] (Figure 1-1). Over time, nodules can progress to the involutional phase of DD where
a collagenous and contractile disease cord forms along the palmar fascia. This process is
associated with an increase in myofibroblasts that impose significant contractile forces
on the palmar fascia [23] and induce permanent contracture of the associated finger(s).
Once finger contracture has occurred, the disease typically enters the final residual phase
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Figure 1-1: Clinical presentation of Dupuytren’s Disease.
In the proliferative stage of DD, a nodule is formed in the palm (Stage A), which then
progresses to a collagenous disease cord in the involutional stage (Stage B). Finally, in
the residual phase of disease (Stage C), the cord tightens which results in permanent
contracture of the affected finger(s) and onset of the residual phase. (Reprinted with
permission from Rehman et al. [178])
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[64] where the contractile cord becomes a heterogeneous structure with regions of
acellular tissue, which are very collagenous, interspersed with cell-rich nodules, referred
to as the “nodule-cord unit” [64]. The abundance of apoptosis-resistant myofibroblasts in
nodules and disease cords is considered both a distinguishing feature and functionally
important component of DD development [65,66], and new therapeutic treatment
strategies are aimed at inhibiting the proliferation and differentiation of myofibroblasts
and/or inducing their apoptosis.
DD is also known as Dupuytren’s Contracture or palmar fibromatosis, and is the most
common inherited connective tissue disorder of Caucasian males over 60 years of age
[67,68]. In Europe, DD prevalence can be as high as 20% over a broader age range
[67,69], while in Western countries, the prevalence of the disease increases with age and
has been estimated to be approximately 15% at 60 years of age and up to 30% at 75 years
[70]. The incidence of DD in the general US population was estimated to be 3 new
diagnosed cases per 10, 000 in 2007 [71]. While males and females have similar global
disease prevalence up to age 45, thereafter males are afflicted 3 to 4 times more often
than females [72]. Almost 40% of patients with DD report that a family member is also
affected, suggesting a strong genetic predisposition to its development [73,74].
Despite being first described in 1831 by Guillaume Dupuytren, more than 150 years later
the etiology of DD remains poorly understood and a cure remains elusive. Both genetic
and environmental factors have a role in determining susceptibility to this disease, as
evidenced by the occurrence of both familial and apparently sporadic cases [73,75,76].
Risk factors for DD have been described, including manual labour, trauma, smoking,
alcohol, diabetes and epilepsy [74,77–80]. While the conclusions drawn from many of
these studies are controversial, the association with diabetes appears to hold true [77], as
the prevalence of DD can be as high as 40% when assessed within a diabetic population
[81,82]. The Dupuytren’s “diathesis” i.e. the list of characteristics that identify an
individual as likely to develop DD, includes palmar bilateral lesions, positive family
history, lesions over the knuckle (Garrod’s pads), Caucasian ethnicity, male gender, and
age at onset of less than 50 years. These factors predict the risk of DD recurrence after
treatment to be more than 70% if the individual satisfies all of these criteria [74]. The
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genetic basis of the Dupuytren’s diathesis remains unclear, and there is an obvious need
to identify the genetic links in DD in order to develop effective treatment strategies for
these patients.

1.6

Treatments for DD

Surgical resection of the disease cord is the current “gold standard” treatment option for
DD patients [71,83], despite this approach resulting in disease recurrence in at least one
of every three patients [74,84,85]. This unsatisfactory outcome occurs despite extensive
and expensive [86] post-operative rehabilitation that negatively impacts patient quality of
life [13]. For some patients, continual recurrence of finger contractures after surgeries
leads them to consider amputation as a final option to eliminate the risk of relapse [87].
Alternative non-surgical interventions have been gaining popularity in recent years,
however these treatments are associated with disease recurrence rates of 50% or higher
[88–90]. These treatments include needle aponeurotomy, where a needle is used to
manually sever and dissect the cord within the hand, and injections of Clostridial
collagenase, an enzyme that breaks down the type I and type III collagen in the cord
[88,91]. In the context of the high disease recurrence rates, there are currently no truly
effective treatment options for DD [92]. A detailed understanding of the molecular
processes that regulate fibroblast proliferation and their subsequent differentiation into
myofibroblasts, as well as the genetic basis of DD, is required to design rational and more
effective molecular therapies.

1.7

Genetics of DD

The increased incidence of DD in the Northern European population and the disease
heritability within families strongly implicates a genetic component to Dupuytren’s
Disease [72,73]. This concept has gained considerable support following a recent study
demonstrating that one twin in a monozygotic male pair is 37% more likely to be affected
by DD if the other has this disease versus just 7% in fraternal male twins [93].
Inheritance of DD is suggested to follow an autosomal dominant inheritance pattern with
variable penetrance [94] and, while numerous studies have sought to identify the
specifics of these genetic links, relatively few insights have been achieved. Chromosome
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instability was suggested to be part of the genetic susceptibility for DD [95] and
comparative genomic hybridization studies were completed to assess the possibilities of
gene copy number variations, however subsequent findings did not support this
hypothesis [96]. Another study reported DNA copy number variations in chromosome 6
near the HLA locus, and chromosome 7 and 14 near the T-cell receptors - γ and -α,
respectively, but the sample size was limited in both studies [97,98] and the general
applicability of the findings are unclear. There has been one genetic linkage study
performed thus far in a Swedish family which identified an association in 16q [94], but
these results are yet to be confirmed. A genome wide association study performed on
European DD patients identified 11 associated single nucleotide polymorphisms (SNPs),
6 of which were located near or within Wnt-related genes [99]. However the effects of
these SNPs on Wnt regulation have not been reported, nor have consistent changes in the
expression of these Wnt genes been detected in some expression analyses of DD cells
[100]. Dysregulated Wnt gene expression was implicated in an exon array study that
compared fibroblasts derived from DD palmar fascia from mostly male patients to
fibroblasts derived from the thigh of female patients unaffected by DD [101]. However,
most of the dysregulated genes that are consistently identified in previous microarray
analyses of DD cells and tissues [98,102–104] were not identified in this exon array
analysis, making it difficult to interpret these results. In summary, while some of the most
recent genetic and transcriptional analyses are consistent in identifying genes that encode
Wnts and/or molecules associated with Wnt signalling as potential contributors to DD
development, their contributions remain controversial and very poorly understood.

1.8

Molecular mechanisms of DD development

TGF-β1 signalling is increased in DD and has been shown to induce myofibroblast
differentiation [58,105] and fibroproliferation [106] of fibroblasts derived from fibrotic
DD tissues (DD cells). As described in 1.4, the concurrent activation of parallel signalling
pathways can direct TGF-β1 signalling intermediates to induce either of these outcomes
in other systems [42]. The Wnt/β-catenin signalling pathway implicated in recent genetic
and transcriptional analyses of DD tissues and cells is one of these parallel signalling
pathways, and cross-talk with TGF-β1 signalling has been shown to elicit effects on
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proliferation and myofibroblast differentiation in other systems [45,107]. Total cellular βcatenin levels are increased in fibrotic DD tissues relative to the adjacent, non-fibrotic
palmar fascia [108] and β-catenin levels in primary DD cells are sensitive to fibrosisassociated changes in ECM tension in vitro [44]. These findings suggest that a detailed
understanding of interactions between the TGF-β1 and Wnt/β-catenin signalling
pathways may provide valuable insights into the molecular mechanisms of DD
development.

1.9

β-catenin

β-catenin is best recognized as a 90 kDa [109] protein intermediate in the canonical Wnt
signalling pathway that has important and mutually exclusive cell signalling and
structural roles [110,111]. Structurally, β-catenin is essential for adherens junction
formation, where it can interact with γ-, α-catenins and E-cadherin to promote the cell-tocell contacts [112,113] required during embryonic differentiation [110]. In addition,
nuclear localization of β-catenin can induce interactions with T cell factor/Lymphoid
enhancer factors (TCF/Lef) or other transcription factors to regulate gene transcription
[114,115]. β-catenin-mediated trans-regulation of gene transcription is required for
mesoderm formation in embryonic stem cells and in mice [110,116], illustrating its
central roles in development. In Homo sapiens, β-catenin consists of 781 amino acids and
can be functionally divided into the N-terminal, central and C-terminal domains [109].
The N-terminal domain is required for β-catenin signalling, but it is the central domain,
which contains 12 armadillo repeats in a rigid scaffold, that is most important for βcatenin function [109]. Many β-catenin binding partners interact with the armadillo repeat
region in β-catenin. E-cadherin interacts with all 12 repeats [117] and TCF/Lef interacts
with 8 of these repeats [118], thereby precluding the simultaneous binding of both
partners [119]. Whether the same pool of β-catenin that is involved in cell-cell contacts is
released to trans-regulate gene transcription in the presence of Wnt signalling is
somewhat controversial, however recent evidence in other signalling pathways is
supportive of this concept [120,121].
Canonical Wnt signalling (Figure 1-2) is integral to cellular proliferation and
differentiation during embryonic development (reviewed in [122,123]). β-catenin is a key
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Figure 1-2: Canonical Wnt Signalling Pathway.
Stimulation of the Frizzled receptor/LRP5/6 by Wnts results in phosphorylation of
Dishevelled (Dvl), which in turn inactivates GSK-3β. Inactivation of GSK-3β allows βcatenin to be released from the destruction complex (which facilitates its degradation in
the absence of Wnts in an ubiquitin-mediated mechanism) and to accumulate within the
cytoplasm, translocate to the nucleus and transactivate the Tcf/Lef transcription
complex. (Reprinted with permission from Bowley et al. [139])
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effector molecule in these processes under the regulation of glycogen synthase kinase
(GSK)-3β. In the absence of a Wnt signal, GSK-3β phosphorylates β-catenin on serine
residues 33 and 37 [124–126] and, with other components of the “destruction complex”
including axin, adenomatous polyposis coli (APC) and casein-kinase 1, targets phosphoβ-catenin to the E3 ubiquitin ligase complex for degradation by the 26S proteasome
[127,128]. Wnt activation of the Frizzled receptor and its co-receptor, low density
lipoprotein receptor-related protein (LRP5/6), facilitates binding with the cytoplasmic
protein Dishevelled [129], phosphorylation of LRP and subsequent inactivation of GSK3β [130]. When the destruction complex is destabilized by the loss of axin and GSK-3β
activity [130] in the presence of Wnts, β-catenin accumulates in the cytoplasm and
translocates to the nucleus to regulate its target genes. Consistent with its central role in
β-catenin signalling, GSK-3β is believed to be the major point of convergence for the
many of the signalling pathways that cross-talk with the Wnt signalling pathway [123].

1.10

β-catenin-mediated transcription

The mechanisms that regulate the nuclear translocation of β-catenin are not clearly
understood, as it does not contain a nuclear localization signal and the signals that induce
nuclear localization appear to vary between different cell types and systems. β-catenin
does not bind DNA, but rather interacts with DNA binding transcription factors in order
to elicit repressive or activating effects on transcription [109,119]. While Wnt-dependent
β-catenin transcription is mainly transduced through TCF/Lef transcription factors, βcatenin can also interact with SMADs or c-Jun/AP-1, or other complexes to regulate
target genes [131–133]. Numerous β-catenin target genes have been documented,
including c-myc [134], cyclin D1 [135], axin2 [136] and epidermal growth factor
receptor [137]. To our knowledge, the majority of the genes that are regulated by or
associated with β-catenin have been identified in cancer cells, and there are currently very
few reports of β-catenin regulated genes in non-malignant cells.

1.11

β-catenin in fibrosis and DD

Increased β-catenin levels and signalling have been reported in many diseases [138–140],
with or without obvious changes in Wnt signalling [43], and activation of this signalling
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pathway is thought to contribute to disease progression by regulating cellular
proliferation. Mutations in the gene encoding β-catenin, CTNNB1, have been reported in
numerous cancers [141–144]. These mutations typically delete or inhibit β-catenin
phosphorylation sites, allowing β-catenin to avoid degradation, translocate to the nucleus
and dysregulate gene transcription. Very little is known about the identities of the genes
that are regulated by β-catenin or the consequences of β-catenin-mediated gene
transcription in fibrosis. One of the few β-catenin gene targets that has been identified is
IGFBP6, encoding Insulin-like Growth Factor Binding Protein (IGFBP)-6 [145].
IGFBP6 expression is reported to be transcriptionally downregulated by β-catenin in
aggressive fibromatosis, and by unknown interactions in DD [145,146]. As β-catenin
levels are increased in DD [44,108], these reports led us to hypothesize that β-catenin has
a similar role in attenuating IGFBP6 expression in DD.

1.12

IGFBP-6

IGFBP6 encodes IGFBP-6, one of the six Insulin-like Growth Factor Binding Proteins
(IGFBP-1 to -6) that bind the peptide growth factors IGF-I and IGF-II with high affinity
[147–149]. While many IGFBPs also have IGF-independent roles [150–153], a major
function of these proteins is to regulate the availability of the IGFs to their primary
signalling receptor, the type I IGF receptor (IGFIR) [147]. IGFBP-6 is the only IGFBP
which displays a 20-100X preference for IGF-II over IGF-I [154–156], making it a
relatively specific inhibitor of IGF-II signalling. Originally isolated from cerebrospinal
fluid, where its levels are highest [157–159], IGFBP-6 is a 23 kDa protein in its native
state, but 28-34 kDa when O-glycosylated in vivo [157]. IGFBP-6, like the other IGFBPs,
consists of 3 distinct N, C and L domains, however it differs from other IGFBPs in
lacking two otherwise conserved cysteine residues in the N-domain. The N and C
domains are highly conserved between all IGFBPs, and the N domain contains the
primary IGF binding site. However, the strong preferential binding affinity for IGF-II by
IGFBP-6 is conferred by its C domain [154,155], a region that is also involved in
binding glycosaminoglycans (GAGs) [160]. IGF-II binding affinity is decreased upon
GAG binding due to overlap between the binding sites in the C domain. There are 5 Oglycosylation sites within the L domain of IGFBP-6 and its glycosylation confers stability
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and protection from proteolysis [161]. Glycosylation also increases IGF-II binding
affinity and inhibits GAG binding, rendering IGFBP-6 a very stable IGF-II signalling
inhibitor [160,162].

1.13

IGFBP6 gene characterization and regulation

The IGFBP6 gene contains four exons spanning 4.7 kb and is found on the long arm of
chromosome 12. The gene does not contain a TATA box or CAAT motifs, however basal
promoter activity is evident within 158 bp of the transcriptional start site [163]. The
IGFBP6 promoter region has a high GC ratio, and its expression can be epigenetically
downregulated by methylation of CpG islands [164]. Retinoic acid is a potent inducer of
IGFBP6 expression and secretion [157,165] and IGFBP6 is considered a p53 responsive,
pro-apoptotic gene in some cell types [166]. Cyclic AMP has been shown to decrease
IGFBP6 expression, and TGF-β [157,167], glucocorticoids, and estradiol have all been
shown to affect IGFBP-6 secretion [157]. Other than a single report in aggressive
fibromatosis implicating roles for β-catenin in the transcriptional downregulation of
IGFBP6 [145], very little is known about trans-regulation of its transcription.

1.14

IGFBP-6 in disease and fibrosis

IGFBP-6 has well documented roles as an inhibitor of cellular proliferation in numerous
systems and cell types [168,169]. It has also been reported to induce apoptosis through
various mechanisms including Ku80 binding [170] and activating early growth response1 (EGR1) expression [168]. Additionally, IGFBP-6 has been shown to inhibit osteoblast
and myoblast differentiation [156,171]. While most reports of IGFBP-6 actions are IGFII dependent, IGF independent effects in promoting cell migration [172] and inhibiting
angiogenesis [173] have been recently reported.
IGFBP-6 levels are dysregulated in many cancer systems [174–176] and increased in the
cerebrospinal fluid of Alzheimer’s patients [158]. The role of IGFBP-6 in fibrosis is not
well characterized to date. IGFBP6 mRNA has been detected in hepatic stellate cells, the
precursors of myofibroblasts in liver fibrosis, however IGFBP-6 protein levels were
undetectable based on an IGF-I ligand blot [177]. Aside from this study, all that appears
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to be known about IGFBP-6 in fibrosis is that IGFBP6 expression in aggressive
fibromatosis and Dupuytren’s Disease is suppressed [145,146]. As IGFBP-6 consistently
inhibits cell proliferation and/or viability in other systems, downregulated IGFBP6
expression and IGFBP-6 levels in fibroses would be predicted to enhance fibroblast
proliferation through IGF-II dependent and/or IGF-II independent processes.

1.15

IGF-II and the IGF2 gene

IGF-II is a 7.5 kDa peptide consisting of 67 amino acids [178], which signals through the
Type I IGF Receptor to elicit effects on apoptosis, proliferation, differentiation, survival,
invasion, migration and a host of other cell behaviours in a variety of systems [179–182].
The IGF2 gene spans 30 kb on chromosome region 11p15, and contains 10 exons with
the functional peptide only encoded by the last 3 exons [183]. IGF2 transcription can be
initiated from 4 distinct promoters, all encoding the same mature IGF-II peptide [183]
(Figure 1-3). Additionally, IGF2 is genomically imprinted and expressed only from the
paternally-derived allele in most mammalian tissues [184].
While the role of IGF-II in fibrosis is poorly understood, IGF-II has been shown to
induce collagen and fibronectin production in pulmonary fibrosis [185], and to induce
myofibroblast differentiation in combination with TGF-β in murine fibroblasts [42].
Thus, increased IGF-II bioavailability would be predicted to contribute to the increased
myofibroblast differentiation and collagen deposition established in Dupuytren’s Disease.
The possible role(s) of IGF-II in DD have not yet been elucidated.

1.16

Summary and rationale

Dupuytren’s Disease is characterized by excessive TGF-β1 signalling, fibroblast
proliferation, collagen deposition and an abundance of apoptosis-resistant myofibroblasts
[61]. TGF-β1 signalling has been shown to increase β-catenin levels in DD [44] and to
repress IGFBP6 expression [157,167]. Additionally, β-catenin levels are upregulated
while IGFBP-6 levels are downregulated in DD and aggressive fibromatoses
[108,145,146]. β-catenin is reported to repress IGFBP6 expression [145] and to enhance
fibroblast proliferation by activating the transcription of proliferation-inducing target
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Figure 1-3: Simplified map of the human IGF2 gene.
The human IGF2 gene consists of 10 exons with exons 8, 9 and 10 (shown in green)
encoding mature IGF-II. Initiation of transcription can occur from any of 4 distinct
promoters (P1-P4), the activity of which are both developmental stage- and tissuespecific.
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genes [135]. Decreased IGFBP-6 levels are predicted to increase IGF-II signalling, and
IGF-II signalling can cross-talk with TGF-β1 signalling to induce myofibroblast
differentiation [42]. Based on these data, the central hypothesis of this thesis is that
increased levels of endogenous TGF-β1 signalling induce β-catenin accumulation and
signalling to repress the expression of IGFBP6 and other genes, the dysregulation of
which, promote DD development. The resulting decrease in IGFBP-6 levels will increase
fibroblast proliferation and/or the differentiation of myofibroblasts through IGF-II
dependent or independent mechanisms in DD.

1.17

Specific objectives of this thesis

The specific objectives of this thesis were:
1) To investigate the interactions between β-catenin, the promoter of IGFBP6 and
IGFBP6 transcription in in vitro models of DD. These studies were subsequently
expanded to identify all of the genes that interact with β-catenin during DD development.
2) To determine the functional consequences of restoring IGFBP-6 to normal
physiological levels and of increasing the levels of IGF-II, the primary ligand of IGFBP6, in in vitro models of DD.
3) To elucidate the mechanisms that dysregulate the expression of IGF2, encoding IGFII, in in vitro models of DD.
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Chapter 2

2

Identification of β-catenin gene targets in Dupuytren’s
Disease patients
2.1

Introduction

β-catenin is a central mediator of the canonical Wnt signalling pathway that plays
essential roles in embryonic development [1–3] and disease progression [4–8]. In the
absence of Wnt stimulus, β-catenin is phosphorylated by glycogen synthase kinase
(GSK)-3β, ubiquitinated and degraded by the 26S proteasome. This process prevents
translocation of β-catenin to the nucleus, and the activity of T cell factor/ lymphoid
enhancer factor (TCF/Lef) transcription factors are inhibited by Groucho/TLE corepressors and the recruitment of histone deacetylases [9]. In the presence of Wnts, GSK3β is phosphorylated and inactivated, allowing β-catenin to accumulate in the cytoplasm
and subsequently translocate to the nucleus. Nuclear β-catenin can displace Groucho/TLE
co-repressors, interact with TCF/Lef transcription factors and recruit transcriptional
activators to its target genes [10].
β-catenin levels and associated trans-regulation of gene transcription can also be
increased by factors other than Wnts. One of these factors is Transforming Growth
Factor (TGF)-β [11–13], which can activate pathways that intersect with the canonical
Wnt signalling pathway to stabilize β-catenin levels, promote its nuclear translocation,
and elicit effects on gene transcription to enhance proliferation [13]. TGF-β-induced
fibroblast proliferation in wound healing and fibrosis is dependent on cytoplasmic
stabilization, accumulation and nuclear transport of β-catenin [14]. Increased β-catenin
signalling and/or levels are reported in aggressive fibromatosis [12], Dupuytren’s Disease
[11,15], lung, kidney and liver fibroses [6,16,17], supporting the hypothesis that βcatenin plays a central role in the hyper-proliferation of fibroblasts that subsequently
differentiate into myofibroblasts in these conditions.
Dupuytren’s Disease (DD) is a benign and heritable fibrosis that is characterized by the
formation of collagenous and contractile disease cords that result in permanent finger
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contracture(s) [18,19]. At a cellular level, excessive TGF-β signalling and the abundance
of apoptosis-resistant myofibroblasts are considered distinguishing features of DD, as
they are of other fibroses [20–22]. The proliferation and differentiation of fibroblasts
within, or in close proximity to, the tissue undergoing fibrosis is considered to be a major
source of myofibroblasts in these conditions, and these processes are potently induced by
TGF-β [23–25]. TGF-β has been shown to increase β-catenin accumulation in
Dupuytren’s Disease [15]; however the transcriptional consequences of the increased βcatenin levels are yet to be reported. TGF-β typically signals through SMADs to elicit its
effects through the TGF-β receptors I and II. SMAD2 and 3 are phosphorylated upon
stimulation with TGF-β, allowing their interaction with SMAD4 to facilitate the entry of
SMADs 2 and 3 into the nucleus to regulate gene transcription. SMAD3 and β-catenin
have been reported to act in concert to induce gene expression [26] and in chondrocytes,
SMAD3 and SMAD4 can act to stabilize β-catenin levels to prevent its degradation and
facilitate nuclear translocation [27]. β-catenin does not bind DNA [28,29], so it must
interact with transcription factors to elicit its actions. In addition to TCF/Lef, β-catenin
can interact with Forkhead box O (FOXO) transcription factors, which prevents
transcription of β-catenin-TCF-Lef target genes [30]. TGF-β signalling can phosphorylate
FOXO3 [31], which leads to its exclusion from the nucleus and the enhanced
transcription of β-catenin-TCF/Lef target genes [30].
The β-catenin target genes identified to date have mostly been reported on an individual
basis in cancer cell lines [32–35]. These gene targets include, amongst others, c-myc,
cyclin D1 and epidermal growth factor receptor (EGFR) [32,34,36–38]. Advances in
bioinformatics have made it feasible to simultaneously identify all of the genes in the
human genome that associate with β-catenin by chromatin immunoprecipitation
sequencing analyses (ChIP Seq). This approach has been used to identify genome-wide
β-catenin associations in two independent studies on colon cancer cells, which were
limited to a single tumour cell line in each case [38,39]. Approximately 2 200 β-catenin
gene targets that could be regulated by interaction with either TCF/Lef or AP-1 sites were
identified in one study, while the other study identified ~ 2 800 gene targets potentially
regulated by TCF/Lef only [38,39]. The relevance of these findings to benign diseases is
currently unclear.
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Very few β-catenin gene targets have been previously identified in any fibrosis. One of
them is IGFBP6, encoding Insulin-like Growth Factor Binding Protein (IGFBP)-6.
IGFBP6 expression was reported to be decreased in aggressive fibromatosis and to be
correlated with β-catenin interactions with TCF3 [12]. Interestingly, IGFBP6 expression
is also significantly decreased in DD, and like aggressive fibromatosis, β-catenin levels
are increased in DD [7,12,15,40]. These findings led to the hypothesis that β-catenin
association with the IGFBP6 promoter region is inversely correlated with its expression,
and that IGFBP6 was one of many other genes that might be differentially regulated by
β-catenin associations during DD development. The aim of this study was to use IGFBP6
as a model β-catenin target gene to gain a more detailed understanding of its
transcriptional regulation in fibroblasts derived from fibrotic DD tissues (DD cells) and
fibroblast from normal palmar fascia (CT cells). In addition, a third category of
fibroblasts were derived from the phenotypically unaffected palmar fascia in a digit
adjacent to DD. These fibroblasts (PF cells) are predicted to be genetically identical to
the DD cells derived from the same patient, and to provide a uniquely powerful set of
controls to identify β-catenin interactions with IGFBP6 and other genes in patients that
may be pre-disposed to DD development. Using these cells as comparators, multi-patient
genome-wide ChIP Seq analyses were performed to identify all of the genes that are
differentially associated with β-catenin in each group. The identification and
characterization of the genes regulated by β-catenin is predicted to yield potential
molecular targets to inhibit fibroblast proliferation and differentiation in DD and
conditions with similar molecular characteristics.

2.2
2.2.1

Materials and Methods
Derivation of primary fibroblasts

Small palmar fascia tissue samples were resected from patients with Dupuytren’s Disease
(DD) and from patients undergoing carpal tunnel release (CT) during surgery at the Roth
| McFarlane Hand and Upper Limb clinic with the approval from the University of
Western Ontario Research Ethics Board for Health Sciences Research involving Human
Subjects (HSREB protocol # 08222E, Appendix C). Patient de-identification and
confidentiality were achieved by assigning numbers to these samples prior to processing.
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All patients received a letter of information and signed consent forms for their tissues to
be used for research purposes. Primary fibroblasts were derived from the disease cord
(DD cells), and from phenotypically normal adjacent palmar fascia of the same DD
patient (PF cells), as genetically matched controls. Lastly, normal CT fibroblasts were
derived from the palmar fascia of patients undergoing carpal tunnel release, with no prior
history of Dupuytren’s Disease (CT cells). Patient demographics for the cell lines used in
these analyses are listed in Table 2-1.
Table 2-1: Patient demographics for cell lines used in the ChIP and ChIP Seq
analyses
Patient
1
2
3
4
5
6
7
8
9
10

2.2.2

Cell Line
244PF/DD
271PF/DD
275PF/DD
276PF/DD
CT24
CT25
CT26
CT27
CT30
CT31

Gender
M
M
M
M
M
F
F
F
F
M

Age
30
58
91
45
66
44
35
48
59
78

Application
ChIP, ChIP Seq
ChIP, ChIP Seq
ChIP, ChIP Seq
ChIP
ChIP
ChIP
ChIP, ChIP Seq
ChIP, ChIP Seq
ChIP
ChIP, ChIP Seq

Chromatin Extraction

DD, PF and CT cells (N = 4) were grown to confluence in 15 – T175 flasks up to passage
3 in 20 ml α-minimal essential media (α-MEM). Chromatin immunoprecipitation was
performed using the SimpleChIP Enzymatic Chromatin IP Kit as per the manufacturer’s
protocol and with minor optimization (Cell Signalling Technologies, Beverly, MA).
Media was aspirated and cells were collected into a 50 ml conical tube and incubated
with 1% formaldehyde in PBS solution for 10 min with rotation. Glycine was added to
the solution to inactivate the formaldehyde crosslinking reaction for 5 min with rotation,
after which it was centrifuged for 5 min at 2000 rpm (Hettich Zentrifugen Universal 32).
The cell solution was washed twice with cold PBS for 5 min with rotation and then
centrifuged. To lyse the membranes, cells were incubated in 10 ml Buffer A (proprietary
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buffer included in the SimpleChIP Kit) for 10 min on ice with inversion every 3 min. The
nuclei were pelleted at 3000rpm for 5 min at 4°C and resuspended in 10 ml Buffer B
(proprietary buffer included in the SimpleChIP Kit) for 10 min on ice for lysis. The
centrifugation was repeated and the pellet was then resuspended in 1 ml Buffer B prior to
nuclease digestion and sonication.
The samples were incubated with 10 µl Micrococcal Nuclease (2000 gel units/µl) for 20
min at 37°C with frequent mixing to digest DNA to ~150-200 bp. The enzymatic reaction
was halted by placing the sample on ice and adding 100 µl 0.05 M EDTA. The nuclei
were pelleted at 13 000 rpm for 1 min at 4°C and the pellet was resuspended into 1 ml
ChIP Buffer (proprietary buffer included in the SimpleChIP Kit) supplemented with
protease inhibitors and phenylmethylsulfonyl fluoride (PMSF). The nuclear suspension
was split into 2 x 500 µl samples and incubated on ice for 10 min. The crude chromatin
extract was sonicated on ice twice per sample with the following settings: 1 sec pulse on,
1 sec pulse off, amplitude = 30, duration = 30 sec. Lysates were centrifuged at 10 000
rpm for 10 min at 4°C to obtain the chromatin preparation and pellets were discarded.
A small sample from the chromatin extraction was used to confirm DNA concentration
and fragment sizes of 150-200 bp, after the DNA was purified on the spin columns
included with the SimpleChIP Kit as per the manufacturer’s protocol. The purified ChIP
DNA was loaded in a 1% agarose gel to determine fragment size by electrophoresis. To
determine DNA concentration, 1 µl of each sample was loaded onto the NanoDrop
Spectrophotometer ND-1000 and quantified.
2.2.3

Immunoprecipitation

For each immunoprecipitation, 15-20 µg of chromatin was diluted into 500 µl samples in
1X ChIP Buffer supplemented with Protease Inhibitor Cocktail. Ten µg of rabbit
monoclonal Histone H3 antibody, 10 µg of rabbit polyclonal β-catenin antibody, 10 µg
rabbit polyclonal SMAD2/3 antibody (all from Cell Signalling Technologies, Beverly,
MA), 4 µg mouse monoclonal RNA Polymerase II antibody (Upstate Biotechnology,
Etobicoke, ON Canada), and 2.5 µg rabbit or mouse IgG were added to each tube and
rotated overnight at 4°C. Thirty µl of ChIP grade Protein G Magnetic Beads were added
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to each sample and rotated at 4°C for 2 hours. Immunoprecipitated (IP) samples were
washed according to the manufacturer’s protocol 3X in a low salt buffer wash, and once
in a high salt buffer containing 5M NaCl. The supernatant was carefully removed and 1X
ChIP Elution buffer was added to each IP sample prior to elution at 65°C for 30 minutes
in a water bath with gentle mixing every 5 minutes. The magnetic beads were discarded
and the supernatant was transferred to a new tube. Proteinase K and NaCl were added to
each eluted chromatin sample and the inputs (containing no antibody) and incubated for 2
hours at 65°C. ChIP DNA was isolated according to the manufacturer’s protocol in the
supplied spin columns. Briefly, DNA Binding Buffer was added to each sample and
transferred to a DNA spin column. Samples were centrifuged for 30 sec at 14 000 rpm
and washed in DNA Wash Buffer and spun down again, discarding the liquid in the
collection tube each time. Fifty µl of DNA Elution Buffer was added and spun at 14 000
rpm for 30 sec. Samples were stored at -20°C until further analysis. For ChIP Seq
analysis specifically, the DNA from 3 individual IPs were isolated in one DNA spin
column in order to achieve enough DNA for the library preparation.
2.2.4

Real Time PCR Analysis

Primers were designed to amplify regions of the IGFBP6 promoter surrounding each of
the TCF sites by real-time PCR after DNA isolation from the ChIP experiments. TCF1_F
5’-TGCTGACAATGAGGTTCGTAT-3’ and TCF1_R 5’GTTATGCAACAGGGACCATC-3’ were used for the TCF1 site located at -1210 to 1204 from the start site in the IGFBP6 promoter. For the TCF2 site, at -155 to -148, the
following primers were used: TCF2_F 5’-CATACACACTAAGTGGATTGC-3’, and
TCF2_R 5’-CTCCCTTTCCAGTTTCTGTT-3’. The PCR procedure employed iQ SYBR
Green Supermix chemistry (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada) and
the following program was run: 50°C for 2 min, 95°C for 10 min, followed by 45 cycles
of 95°C for 15 sec, and 60°C for 1 min on the Bio-Rad CFX384 Real Time System.
2.2.5

Library Preparation

ChIP DNA was quantified using the Qubit Fluorometer High Sensitivity DNA assay
(Invitrogen Corporation, Carlsbad, CA). Ten ng of DNA was required for the library
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preparation using the NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina
(New England Biolabs) and the manufacturer’s protocol was followed with size selection
using AmpureXP Beads. Briefly, ChIP DNA was end-repaired, after which a series of
deoxy-adenosines were added to the DNA. Adaptors compatible with the Illumina
platform were purchased in a NEBNext Multiplex Oligos for Illumina kit (New England
Biolabs) and ligated to the dA-tailed DNA. This ligated DNA-adaptor was enriched by
PCR using the following program: Initial denaturation at 98°C for 30 sec, 15 cycles of
denaturation at 98°C for 10 sec, annealing at 65°C for 30 sec, and extension at 72°C for
30 sec, and lastly, final extension at 72°C for 5 min. These library preparations were then
sent to The Centre for Applied Genomics at the Sick Children’s Hospital in Toronto for
quality control and sequencing. One patient sample did not pass quality control analyses
on the Bioanalyzer, and thus it was excluded from the sequencing run. Thus sequencing
was performed once on 3 different primary cell lines per group (N = 3, n = 1, CT, PF and
DD), corresponding to 6 different patients.

2.2.6

ChIP Sequencing Analysis

All libraries were sequenced on the Illumina HiSeq 2500 across 3 lanes, using v3
chemistry in a multiplex paired end protocol (2x100-bases). Base calling was performed
with the Illumina pipeline 1.8.1. Raw sequence data files (referred to as reads) were
merged and aligned to the hg19 human genome using a PERL script written in-house by
Dr. Greg Gloor (See Appendix D). The aligned reads data were uploaded to the Galaxy
Browser (http://usegalaxy.org) [41–43] where further downstream analysis was
performed. Peaks were called using Model-based Analysis of ChIP Seq (MACS) v1.0.1
[44] using an MFOLD enrichment factor of 5, tag size = 100, bandwidth = 150 and p <
0.05 for forward and reverse read files separately for each sample. The intersect tool in
the BEDtools package [45] available on Galaxy was used to retain only peaks common
between forward and reverse datasets (ie. overlapping). From these, only those peaks that
were common to all 3 patient samples within each group were retained as consistent catenin associations within the human genomes of that group. These peaks were then
intersected with RefSeq files to determine their location within the genome. Peaks that
fell within a gene region were mapped back to the RefSeq file using another PERL script
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(See Appendix E) which isolated the RefSeq accession numbers from each association in
order to obtain a gene identity using NCBI Batch Entrez.
2.2.7

Ingenuity Pathway Analysis

Networks, and disease and biological function associations between the genes isolated
from the ChIP Seq analysis were generated with QIAGEN’s Ingenuity Pathway Analysis
(IPA, QIAGEN, Redwood City, www.qiagen.com/ingenuity). P values were determined
using a right-tailed Fisher Exact test, which calculates the probability that the observed
gene associations to each category are due to random chance. In general, p < 0.05
indicates a non-random association.

2.3
2.3.1

Results
Chromatin Immunoprecipitation (ChIP) Experiments

Increased β-catenin and decreased IGFBP6 levels have been independently reported in
Dupuytren’s Disease (DD) and aggressive fibromatosis [12,15,40]. Denys et al. reported
that the downregulated expression of IGFBP6 in aggressive fibromatosis was due to βcatenin interactions with TCF3, a member of the TCF/Lef transcription factor family, in
the IGFBP6 promoter [12]. To determine whether β-catenin had a role in repressing
IGFBP6 transcription in DD, ChIP analyses were performed on untreated DD, PF and CT
cells as described in the methods. Histone H3 and IgG antibodies were included as
positive and negative controls, respectively, in addition to a no-antibody (input) control.
DNA was isolated from the pull-downs and primers specific to each TCF binding site
within the IGFBP6 promoter were used in the real-time PCR analysis. Two consensus
TCF binding sites have been reported within the IGFBP6 promoter region; the site
designated “TCF1” is located at -1210 to -1204bp and the “TCF2 site” is located from 155 to -148bp from the transcriptional start site of IGFBP6 (Figure 2-1) [12]. As shown
in Figure 2-2A, ChIP analyses revealed similar levels of β-catenin association with the
TCF1 and TCF2 sites in the IGFBP6 promoter of PF cells; however these differences
were not significant (p > 0.05). While β-catenin interaction at the TCF2 site was detected
in CT and PF cells, (compared to the TCF1 site where β-catenin association with IGFBP6
was detected only in PF cells), there were no significant differences in the levels of
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Figure 2-1: Locations of the TCF sites in the IGFBP6 promoter region.
There are 2 TCF sites located within the IGFBP6 promoter region as identified
previously [12]. TCF1 is located at -1210 to -1204 and TCF2 is located at -155 to
-148 from the ATG start site.
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associations. β-catenin association with the TCF sites in the IGFBP6 promoter was
variable across the 4 PF/DD patients (Figure 2-3A & B). Assessed overall, β-catenin
association with the IGFBP6 promoter was lowest in DD cells relative to PF cells and CT
cells, directly correlating with IGFBP6 expression levels in these cells. Histone H3 was
utilized as a positive control for these analyses and found to be highly associated with
exon 3 of RPL30 in DD, PF and CT cells (Figure 2-2B).
TGF-β1 treatment simultaneously represses IGFBP6 levels and enhances cytoplasmic βcatenin accumulation in both DD and aggressive fibromatosis [11,12]. TGF-β signalling
through SMADs can negatively regulate gene transcription [46,47] by recruiting histone
methyltransferases or histone deacetylases to target genes [48,49]. As the IGFBP6
promoter contains multiple SMAD binding elements (CAGA sequences) [26], it was of
interest to determine if SMAD interactions with the IGFBP6 promoter correlated with βcatenin interactions with this gene. Additional ChIP experiments were performed using a
SMAD2/3 antibody to detect either SMAD2 or SMAD3 associations with the IGFBP6
promoter. As shown in Figure 2-2C, little to no SMAD2/3 was shown to associate with
the IGFBP6 promoters of untreated DD cells at the TCF2 site and CT cells at the TCF1
site. SMAD2/3 association with the IGFBP6 promoter was more detectable at the TCF1
site in PF/DD cells and in contrast, more detectable in the control PF and CT cells at the
TCF2 site. These differences in the levels of association did not reach statistical
significance. ChIP experiments were also performed with an RNA Polymerase II
antibody to correlate RNA Polymerase II association with IGFBP6 and IGFBP6
expression in DD and PF cells. As IGFBP6 lacks an obvious TATA box, primers were
designed to span 250 bp upstream of the transcriptional start site based on a report of
basal promoter activity being maintained within 153 bp from the ATG [50]. RNA
Polymerase II was found to be more highly associated with the IGFBP6 promoter of PF
cells than with DD cells (Figure 2-2D), correlating with IGFBP6 expression levels in
these cells. PF cells, which are genetically identical to the DD cells, appear to have βcatenin, SMAD2/3 and RNA Polymerase II located within the IGFBP6 promoter region,
while little or no interactions of these proteins were evident in genetically identical,
patient-matched DD cells.
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Figure 2-2: Association of A) β-catenin, B) Histone H3, C) SMAD2/3,
and D) RNA Polymerase II in CT, PF and DD cells by chromatin
immunoprecipitation.
Chromatin was extracted from primary CT (white bars), PF (grey bars) and
DD (black bars) fibroblasts. Immunoprecipitations were performed using βcatenin (N = 4, n = 1), SMAD2/3 (N = 4, n = 1), and RNA Polymerase II (N
= 2, n = 1) antibodies with Histone H3 (N = 2, n = 1) and species-specific
IgG as a control. β-catenin and SMAD2/3 association with the IGFBP6
promoter was examined at the 2 TCF sites (Figure 2-1). Histone H3
association was assessed within exon 3 of Human RPL30. Mean association
was plotted normalized to IgG (dotted line, below 1 signifies background
noise) with standard error of the mean.
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Figure 2-3: β-catenin association with the A) TCF1 and B) TCF2 sites in the
IGFBP6 promoter by patient.
ChIP experiments were performed to assess β-catenin association with the IGFBP6
promoter region in CT (white bars), PF (grey bars) and DD (black bars) cells. βcatenin association with the IGFBP6 promoter in each patient is plotted relative to
rabbit IgG (dotted line) background at 1.
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2.3.2

ChIP Seq preparation

Having confirmed that the levels of β-catenin association with the IGFBP6 promoter
varied between DD, PF and CT cells, ChIP Sequencing (ChIP Seq) studies were
performed to identify all of the other β-catenin gene targets that varied between these
groups. β-catenin and input ChIP samples were used in this analysis as recommended by
technical reviews of this procedure [51]. In order to prepare the ChIP samples for
sequencing, separate libraries were created for each DD, PF and CT sample (β-catenin IP
and input samples) using commercially available kits compatible with the Illumina
platform. Briefly, 10 ng of DNA for each sample was end repaired, dA-tailed and ligated
to Illumina adaptors to facilitate complementarity for downstream sequencing and for
PCR amplification. The quality of each DNA library was confirmed on a Bioanalyzer (N
= 3 per group, done once n = 1) prior to paired-end multiplex (2x101 bp) sequencing on
the Illumina HiSeq 2500. Approximately 40 million reads were obtained per sample in
the forward and reverse directions, with approximately 80% of these reads aligning
exactly once to the genome. These reads were aligned with the human hg19 genome and
peaks were called using Model-based Analysis of ChIP Seq (MACS) [44].

2.3.3

Selecting peak calling parameters

To our knowledge, there are no previous reports of ChIP Seq analyses of trans-activators
of transcription in samples derived from multiple patients. For this reason, it was
necessary to carefully design de novo parameters for the peak calling portion of the
workflow. As β-catenin association with IGFBP6 in PF cells was previously confirmed
by ChIP, these interactions were used as a baseline parameter in the ChIP Seq analysis.
Peaks were identified in the IGFBP6 promoter in 2 out of 3 PF samples from the forward
analysis, and 1 out of 3 from the reverse analysis (Table 2-2) using a model-fold
(MFOLD) enrichment factor of 5 and a p-value < 0.05, demonstrating a low overall
enrichment in the study. Using these interactions as a baseline measure, these parameters
were stringently applied in the final study to call only those overlapping peaks that
appeared in all 3 patients and in both forward and reverse analyses.
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Figure 2-4: A) Peak numbers and B) overlaps identified during MACS
analysis in CT, PF and DD cells.
Peak calling was performed using MACS, with an MFOLD enrichment = 5 and
p < 0.05. A) Only peaks or β-catenin associations common between forward
and reverse analyses and across all 3 primary cell lines per group (CT, PF and
DD), corresponding to 6 different patients (PF and DD are from the same
patient) were used in downstream ChIP Seq analysis. B) Peak overlaps were
assessed between cell groups using the Intersect tool available with the
BEDtools package in Galaxy.
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Table 2-2: Peaks located within the IGFBP6 promoter region that correspond to the
TCF2 site where β-catenin associates as identified in ChIP analysis
Patient

Forward or
Peak Start
Peak End
Reverse
244 PF
F
53 490 823
53 491 223
275 PF
F
53 490 730
53 491 112
244 PF
R
53 490 735
53 491 096
*Relative to IGFBP6 gene position at chr12: 53 491 220

2.3.4

Position from
IGFBP6 gene*
-397
-490
-485

P-value
0.0109
0.0365
0.0158

Peaks identified by MACS

MACS analysis identified an average of ~400 000 peaks in each CT sample, ~350 000
peaks in each PF sample and ~630 000 peaks in each DD sample. However, when both
the forward and reverse analyses were assessed across all 3 patients in each group, only
1.13%, 0.68% and 1.84% of CT, PF and DD peaks respectively were retained for further
analysis (Figure 2-4A). There were almost 5 times as many β-catenin associations with
chromosomal regions of DD cells than with PF cells, and almost 2.5 times more
associations with DD cells than with CT cells. No peaks were identified at this level of
stringency that overlapped between all three cell types, in all 3 patients, in both forward
and reverse analyses (Figure 2-4B). There was minimal peak overlap between the three
cells types: 51 overlapping peaks were identified between DD and PF cells, 12 between
CT and DD and only 1 between CT and PF.
Interestingly, only 32.4% of the peaks of β-catenin associations with the genomes of the
DD samples, 33.5% of the PF samples, and 43.6% in CT samples fell within a gene or
within 10 kb of a gene (Figure 2-5). The identities of the genes within 10 kb of the
regions of β catenin association were obtained by mapping the peak locations back to the
RefSeq Genebase and a selection are listed in Tables 2-3 (CT cells), 2-4 (PF cells) and 25 (DD cells). These analyses can be interpreted to indicate that more than 65% of the βcatenin associations in DD and PF cells and 55% of the β-catenin associations in CT cells
were with regions of the genome where there are no known genes. The majority of the βcatenin associations with regions of the genome that contain protein encoding genes were
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Figure 2-5: Peak locations within the human hg19 genome by cell type.
Overlapping peaks common across all patients were mapped back to the RefSeq genome to
determine locations of peaks using the Intersect tool in BEDtools. β-catenin associations within
10 kb, introns or exons of a gene were identified. Most of the β-catenin associations are within
regions with no known RefSeq genes.
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Table 2-3: Select β-catenin associations within 10 kb of a gene in CT cells.
RefSeq
Accession
Number

Gene Symbol

Gene Description

Chromosomal
Location

NC_000012.12

ABCD2

ATP-binding cassette, sub-family D (ALD), member
2

12q12

NC_000008.11

ADAMDEC1

ADAM-like, decysin 1

8p21.2

NC_000002.12

ADCY3

adenylate cyclase 3

2p23.3

NC_000005.10

ARHGEF28

Rho guanine nucleotide exchange factor (GEF) 28

5q13.2

NC_000017.11

CCL1

chemokine (C-C motif) ligand 1

17q12

NC_000003.12

CCR2

chemokine (C-C motif) receptor 2

3p21.31

NC_000012.12

CD163

CD163 molecule

12p13.3

NC_000003.12

COL6A5

collagen, type VI, alpha 5

3q22.1

NC_000007.14

EGFR

epidermal growth factor receptor

7p12

NC_000007.14

ELFN1

extracellular leucine-rich repeat and fibronectin type
III domain containing 1

7p22.3

NC_000008.11

EPHX2

epoxide hydrolase 2, cytoplasmic

8p21

NC_000012.12

EPS8

epidermal growth factor receptor pathway substrate 8

12p12.3

NC_000001.11

FAM110D

family with sequence similarity 110, member D

1p36.11

NC_000011.10

FAT3

FAT atypical cadherin 3

11q14.3

NC_000014.9

FBLN5

fibulin 5

14q32.1

NC_000009.12

FCN1

ficolin (collagen/fibrinogen domain containing) 1

9q34

NC_000004.12

FNIP2

folliculin interacting protein 2

4q32.1

NC_000016.10

FOXL1

forkhead box L1

16q24

NC_000006.12

GPR110

G protein-coupled receptor 110

6p12.3

NC_000013.11

GPR183

G protein-coupled receptor 183

13q32.3

NC_000014.9

GSKIP

GSK3B interacting protein

14q32.2

NC_000001.11

HHAT

hedgehog acyltransferase

1q32

NC_000006.12

HIST1H1C

histone cluster 1, H1c

6p21.3
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NC_000006.12

HLA-DMA

major histocompatibility complex, class II, DM alpha

6p21.3

NC_000006.12

HLA-DOB

major histocompatibility complex, class II, DO beta

6p21.3

NC_000001.11

IFI16

interferon, gamma-inducible protein 16

1q22

NC_000001.11

MACF1

microtubule-actin crosslinking factor 1

1p32-p31

NC_000015.10

MAP2K1

mitogen-activated protein kinase kinase 1

15q22.1q22.33

NC_000001.11

MIR197

microRNA 197

1p13.3

NC_000004.12

MIR577

microRNA 577

4q26

NC_000017.11

MIR634

microRNA 634

17q24.2

NC_000019.10

MIR643

microRNA 643

19q13.41

NC_000009.12

MIR873

microRNA 873

9p21.1

NC_000020.11

MMP24

matrix metallopeptidase 24 (membrane-inserted)

20q11.2

NC_000006.12

NKAPL

NFKB activating protein-like

6p22.1

NC_000008.11

NRG1

neuregulin 1

8p12

NC_000005.10

PCDHGA4

protocadherin gamma subfamily A, 4

5q31

NC_000002.12

PDE11A

phosphodiesterase 11A

2q31.2

NC_000005.10

PDE4D

phosphodiesterase 4D, cAMP-specific

5q12

NC_000011.10

PGR

progesterone receptor

11q22-q23

NC_000014.9

PRKCH

protein kinase C, eta

14q23.1

NC_000001.11

PTPN22

protein tyrosine phosphatase, non-receptor type 22
(lymphoid)

1p13.2

NC_000015.10

RASGRP1

RAS guanyl releasing protein 1 (calcium and DAGregulated)

15q14

NC_000014.9

RNASE9

ribonuclease, RNase A family, 9 (non-active)

14q11.2

NC_000001.11

S1PR1

sphingosine-1-phosphate receptor 1

1p21

NC_000018.10

TCEB3B

transcription elongation factor B polypeptide 3B
(elongin A2)

18q21.1

NC_000002.12

TCF7L1

transcription factor 7-like 1 (T-cell specific, HMGbox)

2p11.2

NC_000006.12

TJAP1

tight junction associated protein 1 (peripheral)

6p21.1
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NC_000022.11

TTLL12

tubulin tyrosine ligase-like family, member 12

22q13.31

NC_000013.11

TUBGCP3

tubulin, gamma complex associated protein 3

13q34

NC_000017.11

USP32

ubiquitin specific peptidase 32

17q23.3

NC_000017.11

VTN

Vitronectin

17q11

NC_000001.11

WNT3A

wingless-type MMTV integration site family,
member 3A

1q42

NC_000022.11

WNT7B

wingless-type MMTV integration site family,
member 7B

22q13

Table 2-4: Select β-catenin associations within 10 kb of a gene in PF cells.
RefSeq
Accession
Number

Gene Symbol

Gene Description

Chromosomal
Location

NC_000001.11

ACTN2

actinin, alpha 2

1q42-q43

NC_000010.11

ANXA2P3

annexin A2 pseudogene 3

10q21.3

NC_000004.12

ARAP2

ArfGAP with RhoGAP domain, ankyrin repeat and
PH domain 2

4p14

NC_000001.11

ASPM

asp (abnormal spindle) homolog, microcephaly
associated (Drosophila)

1q31

NC_000020.11

CDH4

cadherin 4, type 1, R-cadherin (retinal)

20q13.3

NC_000020.11

DEFB119

defensin, beta 119

20q11.21

NC_000007.14

EGFR-AS1

EGFR antisense RNA 1

NC_000001.11

ELAVL4

ELAV like neuron-specific RNA binding protein 4

1p34

NC_000022.11

FAM19A5

family with sequence similarity 19 (chemokine (CC motif)-like), member A5

22q13.32

NC_000001.11

FCRL5

Fc receptor-like 5

1q21

NC_000011.10

GAS2

growth arrest-specific 2

11p14.3

NC_000004.12

GNRHR

gonadotropin-releasing hormone receptor

4q21.2

NC_000003.12

GPR15

G protein-coupled receptor 15

3q11.2-q13.1

NC_000006.12

GPR63

G protein-coupled receptor 63

6q16.1-q16.3
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NC_000011.10

GRIK4

glutamate receptor, ionotropic, kainate 4

11q22.3

NC_000003.12

GRM7

glutamate receptor, metabotropic 7

3p26.1-p25.1

NC_000003.12

KCNH8

potassium voltage-gated channel, subfamily H (eagrelated), member 8

3p24.3

NC_000003.12

LINC00879

long intergenic non-protein coding RNA 879

3q11.2

NC_000004.12

LINC01098

long intergenic non-protein coding RNA 1098

4q34.3

NC_000016.10

LOC390705

protein phosphatase 2, regulatory subunit B'', beta
pseudogene

16p11.2

NC_000010.11

MBL2

mannose-binding lectin (protein C) 2, soluble

10q11.2

NC_000018.10

METTL4

methyltransferase like 4

18p11.32

NC_000003.12

MIR1324

microRNA 1324

NC_000021.9

MIR155HG

MIR155 host gene (non-protein coding)

NC_000012.12

MIR3612

microRNA 3612

NC_000019.10

MIR371A

microRNA 371a

19q13.42

NC_000019.10

MIR372

microRNA 372

19q13.42

NC_000003.12

MIR3919

microRNA 3919

NC_000009.12

MIR4290

microRNA 4290

NC_000011.10

MRGPRX1

MAS-related GPR, member X1

11

NC_000002.12

NRXN1

neurexin 1

2p16.3

NC_000011.10

OR10G7

olfactory receptor, family 10, subfamily G, member
7

11q24.2

NC_000012.12

PDE1B

phosphodiesterase 1B, calmodulin-dependent

12q13

NC_000004.12

PGRMC2

progesterone receptor membrane component 2

4q26

NC_000001.11

PPIH

peptidylprolyl isomerase H (cyclophilin H)

1p34.1

NC_000013.11

PRR20A

proline rich 20A

13q21.1

NC_000010.11

PTPRE

protein tyrosine phosphatase, receptor type, E

10q26

NC_000008.11

REXO1L2P

REX1, RNA exonuclease 1 homolog (S.
cerevisiae)-like 2 (pseudogene)

8q21.2

NC_000017.11

RHOT1

ras homolog family member T1

17q11.2
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NC_000008.11

RIMS2

regulating synaptic membrane exocytosis 2

8q22.3

NC_000001.11

S100A9

S100 calcium binding protein A9

1q21

NC_000011.10

SCN3B

sodium channel, voltage-gated, type III, beta
subunit

11q23.3

NC_000015.10

SEMA7A

semaphorin 7A, GPI membrane anchor (John
Milton Hagen blood group)

15q22.3-q23

NC_000011.10

SPON1

spondin 1, extracellular matrix protein

11p15.2

NC_000018.10

TCEB3CL

transcription elongation factor B polypeptide 3Clike

18q21.1

NC_000018.10

TCEB3CL2

transcription elongation factor B polypeptide 3Clike 2

18q21.1

NC_000013.11

TPTE2

transmembrane phosphoinositide 3-phosphatase and
tensin homolog 2

13q12.11

NC_000004.12

USP17L30

ubiquitin specific peptidase 17-like family member
30

4p16.1

NC_000015.10

WDR72

WD repeat domain 72

15q21.3

NC_000019.10

ZNF285

zinc finger protein 285

Table 2-5: Select β-catenin associations within 10 kb of a gene in DD cells.
RefSeq
Accession
Number

Gene Symbol

Gene Description

Chromosomal
Location

NC_000007.14

ADAM22

ADAM metallopeptidase domain 22

7q21

NC_000002.12

APOB

apolipoprotein B

2p24-p23

NC_000017.11

CCL23

chemokine (C-C motif) ligand 23

17q12

NC_000001.11

CD1C

CD1c molecule

1q23.1

NC_000019.10

CD33

CD33 molecule

19q13.3

NC_000001.11

CD58

CD58 molecule

1p13

NC_000001.11

CD84

CD84 molecule

1q24

53

NC_000003.12

CD86

CD86 molecule

3q21

NC_000003.12

CNTN4

contactin 4

3p26.3

NC_000004.12

CXCL13

chemokine (C-X-C motif) ligand 13

4q21

NC_000008.11

DEFB105A

defensin, beta 105A

8p23.1

NC_000019.10

FCGBP

Fc fragment of IgG binding protein

19q13.1

NC_000012.12

FGF6

fibroblast growth factor 6

12p13

NC_000005.10

FGFR4

fibroblast growth factor receptor 4

5q35.2

NC_000002.10

FSIP2

fibrous sheath interacting protein 2

2q32.1

NC_000004.12

GABRG1

NC_000001.11

GBP7

guanylate binding protein 7

1p22.2

NC_000005.10

GHR

growth hormone receptor

5p13-p12

NC_000020.11

GHRH

growth hormone releasing hormone

20q11.2

NC_000001.11

GJA5

gap junction protein, alpha 5, 40kDa

1q21.1

NC_000001.11

GJA8

gap junction protein, alpha 8, 50kDa

1q21.1

NC_000001.11

GJB5

gap junction protein, beta 5, 31.1kDa

1p35.1

NC_000006.12

GPR63

G protein-coupled receptor 63

6q16.1-q16.3

NC_000006.12

GPRC6A

NC_000021.9

GRIK1

glutamate receptor, ionotropic, kainate 1

21q22.11

NC_000002.12

ICA1L

islet cell autoantigen 1,69kDa-like

2q33.2

NC_000009.12

IFNA10

interferon, alpha 10

9p22

gamma-aminobutyric acid (GABA) A receptor,
gamma 1

G protein-coupled receptor, class C, group 6,
member A

4p12

6q22.1
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NC_000009.12

IFNA7

interferon, alpha 7

9p22

NC_000004.12

IL2

interleukin 2

4q26-q27

NC_000016.10

ITGAX

NC_000009.12

LOC642929

general transcription factor II, i pseudogene

9p11.2

NC_000018.10

MIR187

microRNA 187

18q12.2

NC_000013.11

MIR320D1

microRNA 320d-1

13q14.11

NC_000002.12

MIR548F2

microRNA 548f-2

2q34

NC_000020.11

MIR646HG

MIR646 host gene (non-protein coding)

20q13.33

NC_000013.11

MTUS2

NC_000006.12

NKAIN2

NC_000011.10

OR4C45

NC_000011.10

OR51I1

NC_000003.12

OR5H1

NC_000006.12

PKIB

NC_000008.11

POTEA

POTE ankyrin domain family, member A

8p11.1

NC_000005.10

PPP2R2B

protein phosphatase 2, regulatory subunit B, beta

5q32

NC_000013.11

PRR20A

proline rich 20A

13q21.1

NC_000001.11

S100A7A

S100 calcium binding protein A7A

1q21.3

integrin, alpha X (complement component 3
receptor 4 subunit)

microtubule associated tumor suppressor candidate
2
Na+/K+ transporting ATPase interacting 2
olfactory receptor, family 4, subfamily C, member
45
olfactory receptor, family 51, subfamily I, member
1
olfactory receptor, family 5, subfamily H, member
1
protein kinase (cAMP-dependent, catalytic)
inhibitor beta

16p11.2

13q12.3

6q21

11p11.12

11p15.4

3q11.2

6q22.31
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NC_000015.10

NC_000015.10

SNORD109A
SNORD11617

NC_000002.12

SOX11

NC_000018.10

TCEB3CL

NC_000018.10

TCEB3CL2

NC_000019.10

TPM4

NC_000004.12

USP17L13

NC_000004.12

USP17L15

NC_000004.12

USP17L21

NC_000004.12

USP17L30

small nucleolar RNA, C/D box 109A

15q11.2

small nucleolar RNA, C/D box 116-17

15q11.2

SRY (sex determining region Y)-box 11

2p25

transcription elongation factor B polypeptide 3Clike
transcription elongation factor B polypeptide 3Clike 2
tropomyosin 4
ubiquitin specific peptidase 17-like family member
13
ubiquitin specific peptidase 17-like family member
15
ubiquitin specific peptidase 17-like family member
21
ubiquitin specific peptidase 17-like family member
30

18q21.1

18q21.1

19p13.1

4p16.1

4p16.1

4p16.1

4p16.1

located within the intronic regions of those genes rather than their promoters or other
locations.

2.3.5

Vertical analyses: β-catenin associations within each patient

Each set of PF and DD cells derived from the same patient are predicted to be genetically
identical, as Dupuytren’s Disease is a benign fibromatosis and any germline mutations
that predispose patients to DD are predicted to be evident in fibroblasts irrespective of
their disease state. Therefore it was appropriate to perform vertical analyses of the peaks
isolated from each matching PF and DD sample for each of the 3 patients. The amount of
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overlap within each patient cell line differed, further complicating the ability to derive
common features from the analyses. Specifically, patients # 244, 271 and 275 displayed
4.3%, 16.1% and 8.7% overlap between β-catenin associations in PF and DD cells
respectively. When all 3 DD cell lines were assessed relative to their corresponding PF
cells, there were 8 805 regions of β-catenin association in all 3 DD patients, but not their
corresponding PF samples, which translated to 2 792 gene associations within genes or
within 10 kb upstream of a gene. There were 1 544 regions or 547 genes where β-catenin
associated within a gene or within 10 kb upstream of a gene that were specific to all PF
cells assessed relative to all DD cells assessed. From these, 1 438 and 497 unique genes
were identified in DD and PF cells, respectively. Only 51 regions of β-catenin association
were common between PF and DD cells. A selection of the genes identified from the βcatenin associations within intronic regions from these analyses are listed in Appendices
F and G.
Table 2-6: Separating β-catenin associations according to presence within PF cells,
DD cells or both, within each patient.

2.3.6

Patient#

Both DD and PF

PF only

DD only

#244

48 388

250 000

810 000

#271

250 000

500 000

800 000

#275

59 753

310 000

320 000

Ingenuity Pathway Analysis of β-catenin associations within
10 kb of a gene

To determine the networks, diseases and signalling pathways associated with the genes
that had β-catenin associations within 10 kb of their location, Ingenuity Core Analyses
were conducted on the complete lists of genes used to generate Tables 2-3, 2-4 and 2-5.
The top disease and biological function association for all 3 cell types was identified as
“cancer” (Figure 2-6). Other prominent disease and biological function associations in PF
and CT cells were “cell growth”, “proliferation”, “morphology” and “development”.

57

Interestingly, the genes identified in DD cells were mostly categorized as contributing to
pathological, rather than normal or developmental, processes.

2.4

Discussion

β-catenin was shown to associate with the IGFBP6 promoter in both PF and CT cells,
while little to no association of β-catenin with IGFBP6 was evident in DD cells. These
data suggest that there is a direct correlation between β-catenin association with the
IGFBP6 promoter and IGFBP6 mRNA levels in DD, PF and CT cells, and that loss of βcatenin at the IGFBP6 promoter leads to its transcriptional downregulation. This
interpretation is consistent with RNA Polymerase II association with the IGFBP6
promoters in PF cells, but not DD cells, despite these cells being derived from the same
hand of the same patient. Additional patients would have to be assessed to confirm βcatenin association levels with the IGFBP6 promoter, as the results in this study did not
achieve statistical significance, likely due to the small patient sample size. Experiments
confirming whether β-catenin is an absolute requirement for IGFBP6 expression in DD
will be a focus of future studies.
These findings are in direct contrast to a previous report in aggressive fibromatosis
indicating an inverse correlation between β-catenin association and IGFBP6 transcription
[12]. As PF cells are derived from the non-fibrotic palmar fascia of patients with DD,
they might represent “pre-DD” fibroblasts that are somewhere between normal and
diseased at the level of β-catenin interactions with target genes. Changes in β-catenin
association with IGFBP6 or other genes between CT, PF and DD cells may provide
insights into the processes that lead to the eventual downregulation of IGFBP6
transcription in DD cells. TGF-β can further repress IGFBP6 expression in DD and PF
cells, and future studies will focus on elucidating its ability to regulate β-catenin and
RNA Polymerase II association with the IGFBP6 promoter.
The association of SMAD2/3 with the IGFBP6 promoter region demonstrated in this
report may provide some insight into the possible roles of TGF-β in this process. SMADs
may repress gene transcription by recruiting histone methyltransferases or histone
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Figure 2-6: Disease and biological function categories determined by Ingenuity Pathway
Core Analysis of β-catenin associated genes of CT, PF and DD cells.
Genes identified from the β-catenin associations within 10 kb of a gene were input into IPA
(QIAGEN, Redwood City, www.qiagen.com/ingenuity) to determine indirect and direct
relationships between the genes. These genes were then allocated to specific biological
function or disease categories using a right-tailed Fisher’s Exact statistical test to determine a
threshold for significance.
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deacetylases to target genes, and the recruitment of histone deacetylases by TCF/Lef
factors to inhibit transcription has been previously documented [9,48,49]. Preliminary
studies in our laboratory using chaetocin, a histone methyltransferase inhibitor [52],
indicated that treatment markedly induced IGFBP6 expression in DD and PF cells, but
only mildly in CT cells, consistent with differing levels of histone methylation at the
IGFBP6 locus in these cells.
Genome-wide associations of β-catenin were identified in this study by ChIP sequencing
across the genomes of 9 different cell lines derived from 6 different patients. This is the
first study, to our knowledge, to report β-catenin associations with genes in human cells
derived from multiple patients with any fibrosis, or indeed for any disease of any kind.
The β-catenin gene associations identified in the genomes of PF and DD cells may
provide insight into the processes that drive Dupuytren’s Disease progression. During the
vertical analyses, the overlapping regions between PF and DD cells were removed, such
that the peaks that remained were specifically associated in PF cells or in DD cells.
Identical genes within these DD and PF lists are present because β-catenin is associating
with different regions of the gene in these 2 cell types, which could be due to β-catenin
transactivation of different transcription factors or the same transcription factor binding
another area. In addition, overlap was evident between β-catenin association with genes
encoding related, but different factors in DD, PF and CT cells. For example, while
FGF14 was identified as a β-catenin associated gene in all 3 cell types, FGF12 was
specifically identified in DD cells and CT cells, while FGF10 was identified only in CT
cells. Interestingly, FGF10 expression has been shown to attenuate fibrosis in mice [53],
which would suggest that β-catenin is required for its expression in CT cells, and that it
may be transcriptionally downregulated in DD in a similar manner to IGFBP6. Different
fibroblast growth factors may have distinct temporal roles in the fibroproliferation in DD
and each may contribute uniquely to disease progression. The potential for different
FGFs to perform distinct functions is yet to be explored in DD. Interestingly, β-catenin
associated with many different genes encoding cadherins in DD cells, while β-catenin
associated more often with genes encoding protocadherins in PF and CT cells (See
Appendices F and G). Additionally, β-catenin associations with numerous collagen genes
were identified in these analyses, supporting previous suggestions that β-catenin may
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have a role in regulating collagen expression [54–56]. As excess collagen deposition is
characteristic of essentially all fibroses including Dupuytren’s Disease, it is feasible that
β-catenin may transactivate expression of these genes. Previous microarray data reports
for DD indicate that COL18A1 and COL6A1 are upregulated in DD nodule tissue relative
to external control tissue [40], consistent with the hypothesis that β-catenin might
promote the transcriptional activation of these collagen genes.
β-catenin has been reported to associate with a variety of genes in many cell types, the
majority of which were derived from cancers or other diseased tissues. This is the first
study to our knowledge to identify the genes that β-catenin associates with in normal (in
this case, palmar fascia-derived) fibroblasts. CT cells were shown to exhibit intermediate
levels of β-catenin association with various genes relative to the levels of interactions
evident in DD and PF cells. Remarkably, no overlapping peaks of β-catenin association
were identified in all 3 cell types. This implies that β-catenin association with genes is
distinct in normal palmar fascia fibroblasts derived from patients without DD, and normal
palmar fascia fibroblasts derived from patients with DD in an adjacent digit. These
findings may suggest that the development of DD is incremental, and that normal
fibroblasts (CT cells) progress to fibroblasts that are “primed” for disease development
(PF cells) to diseased fibroblasts (DD cells). β-catenin interactions may contribute to this
intricate process by trans-regulating gene expression in a specific manner. The single
peak overlap between PF and CT cells suggests that it might be possible to identify
genetic biomarkers that distinguish an individual who is genetically predisposed to
disease development from an individual who is not.
The majority of β-catenin gene associations identified in this study were localized within
intronic regions. Introns have been shown to regulate gene expression in a variety of
systems [57], and in some cases may have more influence on gene expression than the
promoter [58]. This has been definitively demonstrated for Arabidopsis profilin genes,
where swapping intron 1 of vegetative profilin-2 with intron 1 of reproductive profilin-5
led profilin-5 to express a more vegetative profilin-2 pattern [58]. These findings have
contributed to the acceptance of introns playing more important roles in mediating gene
expression in humans than was previously thought [57]. For example, IGFBP6
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expression can be induced by retinoid X receptor activation of an AP-1 site within its first
intron [59] and Ubiquitin C expression can be enhanced by Yin Yang 1 trans-activation
within its first intron [60]. Interestingly, when this intronic region is moved upstream of
the promoter, Yin Yang 1 can no longer affect Ubiquitin C expression, indicating a
spatial dependence for intron-mediated enhancement of transcription. Additionally,
removal of regulatory regions for splicing can diminish gene expression, demonstrating
that splicing is also required for optimal gene expression [60]. As such, intronic regions
also function as areas where splicing is regulated, and this may be another reason for βcatenin association within these regions. While most of the β-catenin gene associations
were within intronic regions, more than 50% were located in regions of the genome with
no known genes, the significance of which is currently unknown.
The Ingenuity pathway analysis provided further insight into the types of genes being
regulated by DD, PF and CT cells. In all 3 cell types, cancer was the top
disease/biological function category which was identified based on the β-catenin gene
associations. While these gene associations may truly reflect a similar disease mechanism
between DD and cancer, this can also be the result of the bias in the literature towards
cancer research and development, as IPA creates its categories based on the research
available in multiple databases. Nonetheless, associations between DD and cancer
development have been identified in a few studies [61,62]. Interestingly, despite the
minimal overlap in peaks between PF and CT cells, the biological function categories
determined from the gene lists were similar, identifying cell proliferation, morphology
and development as significant, which confirms previous reports listing β-catenin as a
mediator of cell proliferation [7,30,63]. In contrast, the top 10 categories in DD cells
were all pathological processes, supporting the concept that molecular therapies must
achieve normal homeostasis in the palmar fascia, rather than just the absence of disease,
to prevent DD progression.
While many previous studies have identified specific TCF/Lef targets, only 2 studies in
human colon cancer cells have looked specifically for β-catenin gene targets throughout
the human genome [38,39]. In HCT116 cells, 2 168 β-catenin gene targets were
identified, while 2 794 were identified in SW480 cells, both of which are comparable to
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the 2 792 β-catenin gene targets identified in this study of DD cells [38,39]. While there
was little overlap between the genes identified in SW480 and DD cells, this could be due
to the adenomatous polyposis coli mutation in SW480 cells which stabilizes β-catenin,
and may in turn affect β-catenin-mediated gene transcription. Surprisingly, there were
only 168 genes which overlapped between the two studies on HCT116 and SW480 cells
[39], which may be the result of the additional transcription factor, AP-1 possibly playing
a role in mediating β-catenin effects on transcription in HCT116 cells [38], but not
SW480 cells. Many Wnt genes were identified as β-catenin gene targets in SW480 cells
[39]. In the current study, Wnt-associated genes were identified mostly in CT cells, which
might suggest that the Wnt pathway is turned off in DD cells, since our lab was unable to
detect any consistent changes in Wnt gene expression in DD cells relative to non-fibrotic
cells [64]. Lack of Wnt involvement in DD may also be the result of SNPs located within
Wnt genes, as identified in a genome wide association study of DD cells where 6/11
SNPs were reportedly within Wnt genes. Based on these data, it was hypothesized that
SNPs in Wnt genes may pre-dispose patients to DD [65].
In contrast, considerable overlap was evident between the HCT116 study and this study
in terms of the gene families that were identified, although the specific members of those
gene families differed. For example, ADAM 12, ADAM19 and ADAMTS16 were
identified as β-catenin gene targets in colon cancer while ADAMs 2, 5, 18, 19, 22, 29, 32,
TS16, TS18, TS19 and TS20 were identified as β-catenin gene targets in DD. ADAM12 is
a highly up-regulated gene in DD [40,66] where it is believed to function as an adhesion
molecule and an IGFBP protease [67]. It is currently unclear if the up-regulated
expression of ADAM12 in colon cancer and DD is the result of distinct mechanisms, or if
the association between β-catenin and ADAM12 in DD was excluded due to the
stringency of peak calling parameters implemented that required peaks to be identified in
all 3 patients in forward and reverse analyses.
Currently, there is a lack of standards and guidelines for assessing ChIP sequencing data
derived from multiple patients. Many algorithms for analyzing multiple datasets focus on
integrating ChIP Seq studies performed by various groups [68–70]. Unfortunately, peak
calling can be achieved through multiple approaches that can vary between analyses,
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adding an additional layer of complexity to an integrative analysis of multiple studies. In
this study, each patient was assessed individually and the data was compared after peak
calling was complete. Between-patient variability made this a very difficult and complex
process, as each patient displayed different levels of β-catenin association within their
genome despite beginning the analyses with similar numbers of reads. β-catenin
association was much higher in the DD cells derived from two of the three DD patients
assessed, while the levels of β-catenin association was comparable between the PF and
DD cells derived from the third patient (Table 2-6). A recent publication identified
jMOSAiCS (joint model-based one- and two-sample analysis and inference for ChIP) as
a new ChIP Seq software specifically designed to analyze multiple datasets by controlling
for the different amount of enrichment between samples [71]. It has also been optimized
to work for trans-acting transcriptional regulators, such as β-catenin. Current algorithms
are optimized either for cis-acting transcription factors or for histone modifications, as
the nature of the peaks derived from each analysis differ (sharp peaks for transcription
factor interactions versus broad peaks for histone marks) [72]. It is unclear if a transacting factor like -catenin would be expected to generate sharp or broad peaks, making
it difficult to select an optimal program. While jMOSAiCs does seem to address many
issues that are faced by researchers analyzing ChIP Seq data derived from clinical
isolates, it is best equipped to handle two different datasets, making it less than ideal for
this study.
A limitation of the current study is that β-catenin enrichment was low, which made it
difficult to identify significant peaks over background input “noise”. Increasing DNA
concentration, and/or testing more β-catenin antibodies for use with ChIP Seq would be
required to optimize the enrichment [73]. It is important to note that this study was
limited to identifying significant levels of association between β-catenin and the human
genomes derived from the various cell types. These analyses did not address the
consequences of these interactions in terms of gene transcription. Additional studies will
be required to independently confirm the associations reported in this analysis and to test
the effects of β-catenin association with the expression of specific candidate genes of
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interest. Confirmatory ChIP and the corresponding PCR analyses for a selection of the
genes identified in this study will be the focus of future studies.
In summary, β-catenin-mediated trans-regulation of gene transcription is likely to
contribute to the development of Dupuytren’s Disease, as it does many other diseases
[7,74]. IGFBP6 was confirmed as a target of β-catenin interactions in PF and CT cells,
which display relatively robust IGFBP6 expression, whereas this association was
attenuated in DD cells. The lack of β-catenin interactions with the IGFBP6 promoter in
DD cells is likely to contribute to the down-regulated IGFBP6 expression in these cells.
A large number of additional β-catenin target genes were identified that were specific to
DD cells, and detailed analyses of their transcriptional regulation are likely to provide
novel insights into their contribution to fibrosis development. These genes may also have
potential as biomarkers to distinguish individuals predisposed to developing DD from the
non-predisposed population. Chapter 3 will focus on elucidating the functional
consequences of IGFBP-6 downregulation and subsequent increased IGF-II signalling in
DD.
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3

IGF-II and IGFBP-6 regulate cellular contractility and
proliferation in Dupuytren’s Disease
3.1

Introduction

Dupuytren's Disease (DD) is a debilitating condition of the hand [1,2] characterized by
the formation of collagenous cords in the palmar and/or digital fascia and permanent
finger contractures. Despite being amongst the most common inherited connective tissue
diseases [1–4], the etiopathology of DD has remained elusive since its description in the
1830s [5]. While microsurgical excision [6] of the contractile cord tissue can temporarily
restore dexterity, this and other treatment approaches fail to prevent disease recurrence in
more than 30% of patients [7–10]. There is a clear need for a better understanding of the
molecular pathology of DD to achieve more effective therapeutic approaches.
Due to the unique physiology of the palmar fascia and the lack of understanding of DD at
a molecular level, there are no established animal or immortalized cell models in which
to study DD development. We take the approach of comparing primary fibroblasts
derived from surgically resected DD contracture (cord) tissue (DD cells) to fibroblasts
derived from the palmar fascia of the adjacent, phenotypically unaffected digit exposed
during surgery (PF cells). While DD may be associated with increased cancer mortality in
some populations [11,12], patients with a family history of finger contractures do not
display any major chromosomal rearrangements or deletions [13] and DD is considered a
benign, heritable fibrosis [4]. Single nucleotide polymorphisms (SNPs) have been
identified as potential markers of this heritability [14], and these polymorphisms are
predicted to be present in all somatic tissues in these patients rather than limited to
diseased tissues. PF cells can therefore be viewed as genetically matched “latent disease”
cells that carry the same predisposing SNPs as DD cells, making them the ideal controls
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for studies of the molecular mechanisms that promote disease development in this
population. In addition, we derive a second control group of palmar fascia fibroblasts (CT
cells) from patients with no history of DD who are undergoing surgeries for unrelated
reasons, such as carpal tunnel release. We consider CT cells to be normal controls and
useful comparators to patient matched PF/DD cells in studies designed to identify
characteristics that are specific to cells predisposed to DD development [15,16].
Using these unique cell models, we have focused on identifying molecules that regulate
the proliferation and differentiation of palmar fascia fibroblasts into myofibroblasts, the
hyper-contractile cell type that remodels the palmar fascia to induce finger contractures in
DD. Several research groups have previously reported gene expression analyses of DD
tissues or cells with the aim of identifying dysregulated genes with potential roles in
myofibroblast development [13,16–20]. Our previous studies have focused on TGF-β1,
encoding transforming growth factor-β1 (TGF-β1) and TGF-β-induced genes such as
periostin [21]. In parallel, we and others [19] have identified IGFBP6 as a significantly
downregulated transcript in DD tissue. The relevance of downregulated IGFBP6
expression to the proliferation and differentiation of palmar fascia fibroblasts into DD
myofibroblasts has not been previously explored.
IGFBP6 encodes insulin-like growth factor binding protein (IGFBP)-6, one of a family of
six secreted proteins that bind insulin-like growth factors (IGFs)-I and -II with high
affinity and regulate their bioavailability [22]. While most IGFBPs can regulate the
availability of both IGF-I and IGF-II under normal physiological conditions, IGFBP-6 is
unique in displaying a 50 fold higher affinity for IGF-II [23,24], identifying it as an IGFII-specific binding protein under normal physiological conditions [23].
In this study, we demonstrate that IGFBP6 mRNA and IGFBP-6 protein levels are
downregulated components of DD cells, and that IGF2 mRNA and IGF-II peptide levels
are upregulated in DD cells relative to controls. Recombinant IGFBP-6 was found to
attenuate the proliferation of DD, PF and CT cells, and co-treatment with IGF-II was
ineffective at neutralizing these effects. IGF-II significantly enhanced DD cell
contractility and this effect could be abrogated by IGFBP-6. Overall, these findings
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implicate IGFBP-6 and IGF-II as previously unrecognized regulators of DD cell
proliferation and contractility that may have potential as therapeutic targets in this and
related fibrocontractile diseases.

3.2
3.2.1

Materials and Methods
Clinical specimen collection

Surgically resected Dupuytren's disease cords were collected from patients undergoing
primary surgical resections at St Joseph's Hospital, London, Ontario. Samples of
phenotypically normal palmar fascia tissue exposed during surgery were collected from
an adjacent, visually unaffected digit for comparative analyses. None of these patients
were being treated for recurrent disease. In addition, small samples of palmar fascia were
collected from patients without Dupuytren's disease who are undergoing hand surgery for
unrelated reasons, such as carpal tunnel release, in which the palmar fascia was
phenotypically unaffected. All subjects provided written informed consent and specimens
were collected with the approval of the University of Western Ontario Research Ethics
Board for Health Sciences Research involving Human Subjects (HSREB protocol #
08222E).

3.2.2

Immunohistochemistry

Surgically resected DD cord and patient matched, phenotypically normal palmar fascia
samples were fixed in 10% formalin prior to dehydration, paraffin embedding and
microtome sectioning. Paraffin-embedded specimens were sectioned (5 μm), dewaxed,
rehydrated and treated with a 3% hydrogen peroxide solution to quench endogenous
peroxidase activity. Slides were treated with a serum-free blocking reagent (Background
Sniper, Biocare Medical, Concord, CA) for 10 min and rinsed in PBS prior to incubation
with rabbit polyclonal IGFBP-6 (Austral Biologicals, San Ramon, CA) overnight at 4 °C.
After a wash in PBS, the slides were incubated (30 min, 22 °C) with a biotinylated
secondary anti-rabbit antibody (Vector Labs, Burlington ON), washed briefly in PBS, and
incubated (30 min, 22 °C) with avidin/biotin/HRP complex (Vector elite PK-6100,
Vector Labs, Burlington ON). Finally, the slides were washed with PBS, and incubated
(1 min) in an enhanced diaminobenzidine (Cardassian DAB; Biocare Medical, Concord,
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CA). Sections were counterstained with methyl green (10 min), dehydrated, cleared, and
mounted with Permount (Fisher Scientific, Ottawa, ON).

3.2.3

Primary cell culture

Primary fibroblasts were isolated from surgically resected DD cord tissues (DD cells),
phenotypically normal (non-fibrotic) palmar fascia tissue from an adjacent, visually
unaffected digit (PF cells) and normal palmar fascia (CT cells) as previously described
[25]. The cultures were maintained in α-MEM-medium supplemented with 10% fetal
bovine serum (FBS, Invitrogen Corporation, Carlsbad, CA) and 1% antibiotic–
antimycotic solution (Sigma-Aldrich, St. Louis, MO). All primary cell lines (DD, PF and
CT cells) were assessed at the lowest passage number achievable up to a maximum of 6
passages, after which the cells were discarded. No changes in cell morphology,
growth/viability or contractility attributable to serial passage were evident in these cells.

3.2.4

Real time PCR

Total RNA samples from primary DD, PF and CT cells were assessed for quality on an
Agilent 2100 Bioanalyzer. 2 μg of high quality total RNA was reverse transcribed into
cDNA first strand using the High-Capacity cDNA Archive Kit (Applied Biosystems) in
accordance with the manufacturer's instructions. TaqMan gene expression assays were
used to measure IGFBP6, IGF2 and IGF1 expressions. IGFBP6 (Hs00181853_m1) and
IGF2 (Hs01005963_m1) expressions were measured relative to the RPLP0 endogenous
control (Hs99999902_m1), and IGF1 (Hs01547656_m1) was measured relative to
GAPDH (Hs99999905_m1) using the ΔΔCT method after confirmation of parallel PCR
amplification efficiencies on a Real-Time PCR ABI Prism 7500. PCR reactions were
carried out under the following conditions: Initial denaturation at 95 °C for 5 min
followed by cycles of denaturation (95 °C for 15 s), primer annealing (60 °C for 1 min)
and transcript extension (50 °C for 2 min) for 45 cycles.

3.2.5

Western immunoblotting

Surgically resected tissues were snap-frozen in liquid nitrogen and protein extracts were
prepared using a tissue bio-pulverizer and PhosphoSafe Protein Extraction Buffer (VWR,
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Mississauga, ON). Cultured cells were lysed in RIPA Cell Lysis Buffer (Teknova Inc.,
Hollister, CA) supplemented with protease inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO), 0.1 M NaF, 10 mM PMSF and 10 mM sodium orthovanadate and placed on ice for
30 min after needle aspiration. After centrifugation to remove insoluble material, total
protein concentrations were determined by BCA analysis. Gel electrophoresis on a 15%
polyacrylamide gel and Western immunoblotting were performed using standard
procedures, and proteins were visualized using enhanced chemiluminescence (ECL). The
primary antibodies utilized were mouse monoclonal IGF-II (Upstate Biotechnology,
Etobicoke, ON) and mouse monoclonal β-actin (Santa Cruz Biotechnology, Dallas, TX).
Total protein levels were assessed by Ponceau S staining (Sigma Aldrich, Oakville, ON,
Canada).

3.2.6

Quantitative IGFBP-6 immunoassay

The levels of secreted IGFBP-6 in DD and PF cell conditioned media were assessed
using the Luminex xMAP fluorescent bead-based technology (Luminex Corporation,
Austin, TX) and the Bio-Plex 200 readout system according to the manufacturer's
instructions (Bio-Rad Laboratories Inc., Hercules, CA). IGFBP-6 levels were calculated
from standard curves of recombinant IGFBP-6 in a solution using Bio-Plex Manager
software (v.4.1.1, Bio-Rad).

3.2.7

WST-1 cell proliferation assay

The WST-1 assay (Roche, Mississauga, ON, Canada) was adapted to measure changes in
the proliferation of primary fibroblasts grown on type-1 collagen, the most abundant
protein component of palmar fascia. We have included type-1 collagen substrates in all
our assays to more closely replicate in vivo conditions. In brief, 2 × 103 cells were plated
in α-MEM/2% FBS in 4 × 96 well trays pre-coated with 60 μl of type-1 collagen (1.8
mg/ml), treatments or vehicles were added, and the trays were incubated at 37 °C for 7
days. WST-1 reagent was added to the wells on days 1, 3, 5 and 7 to allow cleavage of
the tetrazolium salt to formazan by cellular mitochondrial dehydrogenases. Equal
volumes of supernatant were transferred to additional 96 well trays and absorbance
measurements were taken at 450 nm and 650 nm (reference wavelength). This assay
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measures electron transport across the plasma membrane of dividing cells, and thus
functions as an indirect measure of viable cell proliferation. We interpret the outputs as
net proliferation (total cell number changes due to the combined effects of mitogenesis
and apoptosis). All experiments were performed at least three times on a minimum of 4
DD, PF and CT cell lines, each assessed in triplicate.

3.2.8

Fibroblast populated collagen lattice assays

Collagen contraction assays were carried out using modified versions of Bell et al. [26]
and Tomasek and Rayan [27]. In brief, the contractility of DD, PF and CT cells at low
passage (≤6) was assessed in three-dimensional fibroblast populated collagen lattices
(FPCLs). Collagen lattices were cast in 24-well tissue culture trays with each well
containing 400 μl collagen (final collagen concentration of 1.8 mg/ml), 100 μl
neutralization solution, treatment or vehicle, and 1 × 105 cells. FPCLs were maintained in
α-MEM supplemented with 2% FBS and 1% antibiotic–antimycotic solution at 37 °C in
5% CO2. For “relaxed” FPCLs (rFPCLs), lattices were allowed to polymerize for 1 h
before being gently released from the sides and bottoms of the wells using a metal rod.
Relaxed FPCLs typically undergo gradual lattice contraction over 24 h in tissue culture
media. Floating lattices for rFPCLs were digitally scanned at 24.0 h only. For “stressed”
FPCLs (sFPCLs), the collagen lattices remained attached to the wells for 72 h to allow
the cells to induce (and respond to) stress within the lattice and differentiate toward a
contractile myofibroblast phenotype [28]. Lattices were released after 72 h, typically
resulting in rapid contraction over 6 h. Floating lattices for sFPCLs were digitally
scanned at release (0 h), 0.5 h, 1.0 h, 2.0 h and 6.0 h. The areas of individual lattices in
rFPCLs and sFPCLs were determined using the freehand tool in ImageJ software.
Sequential area calculations were then normalized to the area of the lattice (i.e. the area
of the well in which the lattice was cast) prior to release. All experiments were performed
on a minimum of 3 and a maximum of 10 DD, PF and CT cell lines, each assessed in 3
separate experiments, in triplicate.
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3.2.9

Statistical analyses

Statistical analysis was conducted using SPSS v. 17 and Microsoft Excel 2007 statistical
software. For sFPCL data, repeated measures analysis of variance analyses were used to
assess the significance of treatment effects and treatment/time interactions to distinguish
overall treatment-induced changes in contractility from treatment induced changes in
contractility that became significant over time. Significant treatment/time interactions
were further assessed with simple main effects analyses to determine at which time point
a treatment had a significant effect. Paired t-tests were used to determine significant
changes in contractility at 24 h in rFPCLs and in proliferation by change score analysis
between day 7 and day 1. Results were deemed significant when p < 0.05.

3.3
3.3.1

Results
IGFBP6 mRNA and IGFBP-6 levels are attenuated in
Dupuytren's disease tissues and in DD cells

While IGFBP6 has been identified as a significantly downregulated gene transcript in
gene array studies comparing DD tissues to phenotypically unaffected palmar fascia
[19,20], corresponding changes in IGFBP-6 levels have not been reported. As shown in
Figure 3-1A, decreased IGFBP-6 immunoreactivity was evident in paraffin-embedded
sections of DD cord relative to visibly unaffected palmar fascia tissue from an adjacent
digit in the same patient (Figure 3-1B). This decrease in IGFBP-6 immunoreactivity in
DD tissue was despite an inverse disparity in the number of palmar fascia cells (stained
with methyl green in Figure 3-1A and B) in DD cord tissues and the adjacent palmar
fascia. To confirm the cellular source of IGFBP-6 in DD tissues, we assessed IGFBP6
expression in primary fibroblasts derived from diseased palmar fascia (DD cells) relative
to primary fibroblasts derived from the adjacent, phenotypically unaffected palmar fascia
of the same patients (PF cells). As shown in Figure 3-1C, IGFBP6 mRNA levels were
significantly lower in DD cells than in genetically matched PF cells. We also assessed
IGFBP-6 secretion in DD and PF cells, and compared these levels to primary fibroblasts
derived from normal palmar fascia from unrelated patients undergoing treatment for
unrelated conditions (CT cells). IGFBP-6 secretion was significantly reduced in DD cells
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Figure 3-1: IGFBP6 expression and IGFBP-6 secretion are downregulated in
Dupuytren's disease (DD).
Sections of paraffin embedded phenotypically normal, unaffected palmar fascia
tissue (A) and DD “cord” tissue (B) from the same patient were assessed for
IGFBP-6 immunoreactivity, evident as brown (diaminobenzidine, DAB) staining.
Palmar fascia fibroblasts were counter-stained with methyl green. C) QPCR
analysis of IGFBP6 mRNA levels in primary fibroblasts derived from
phenotypically unaffected palmar fascia (PF cells) and DD cord tissue (DD cells)
from the same patients (* = p < 0.05 for DD vs PF samples, N = 3, n = 3). D)
IGFBP-6 secretion by normal palmar fascia fibroblasts (CT cells), PF cells and DD
cells in serum free media over 48 h (* = p < 0.05 for DD vs CT samples, N = 3, n =
1).
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Figure 3-2: IGF2 expression and IGF-II levels are upregulated in DD.
A) QPCR analysis of IGF2 mRNA levels in CT, PF and DD cells (* = p < 0.05 for
DD vs CT samples, N = 6, n = 1). B) QPCR analyses of IGF1 and IGF2 mRNA
levels in primary PF cells (grey bars) and DD cells (black bars) (* = p < 0.05 for
DD vs PF samples, N = 6, n = 1). C) Representative Western immunoblotting
analyses of DD and PF cell lysates and normal palmar fascia tissue (CT) and DD
cord tissue lysates with an IGF-II antibody. Molecular weight (MW) markers are
indicated in kDa. Immunoblotting for β-actin and Ponceau S staining for total
protein (the major protein band at 67 kDa, albumin, is shown) confirmed equal
protein loading. Tissue culture media samples with or without recombinant IGF-II
(rIGF-II) were included as negative and positive controls.
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relative to PF cells and CT cells over 48 h when cultured under identical serum free
conditions (Figure 3-1D).

3.3.2

IGF2 mRNA and IGF-II levels are increased in DD cells

As IGFBP-6 has been reported to elicit effects by sequestering IGF-II, we assessed basal
IGF2 expression in DD and PF cells. IGF2 mRNA levels were consistently (n = 6
patients) and significantly (p < 0.05) increased in DD cells relative to patient-matched PF
cell controls and non-patient-matched CT cells (Figure 3-2A). In contrast to IGF2, the
expression of IGF1, encoding Insulin-like Growth Factor-I, was unchanged between DD
and PF cells (Figure 3-2B). To determine if increased IGF2 expression resulted in
increased IGF-II secretion, we assessed IGF-II levels in DD cord tissue and DD cell
lysates. As shown in Figure 3-2C, IGF-II immunoreactivity was increased in DD tissue
and cell lysates relative to normal palmar fascia tissue and PF cell lysates. Multiple bands
correlating with precursor forms of IGF-II, including “big” IGF-II and variably
glycosylated pro-IGF-II previously reported in human serum [29] were evident in all cell
lysates. As our findings indicated reciprocal changes in IGFBP6 and IGF2 mRNA levels
and IGFBP-6 and IGF-II protein levels in DD cells relative to controls, we compared the
effects of recombinant IGFBP-6 and recombinant IGF-II, individually and in
combination, with or without TGF-β1, on the net proliferation and contractility of DD
and PF cells.

3.3.3

IGFBP-6 attenuates DD cell proliferation in an IGF-II
independent manner

Based on our analyses of IGFBP-6 secretion by CT cells (Figure 3-1D) and previous
studies in tumor cells [30], we chose to assess the effects of 400 ng/ml of recombinant
IGFBP-6 on net cellular proliferation. As shown in Figure 3-3A, a single treatment with
400 ng/ml of recombinant IGFBP-6 on day 0 induced a significant reduction in DD (p <
0.01), PF and CT (each p < 0.05) cell proliferation. As TGF-β1 is an established
component of DD [31], and has been shown to deplete IGFBP-6 secretion in human
fibroblasts [32], the effects of TGF-β1 on proliferation of CT, PF and DD cells were also
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Figure 3-3: IGFBP-6 attenuates the proliferation of DD, PF and CT cells.
Net proliferation (growth and/or apoptosis) of CT (white bars, N = 3 patients, n =
3), PF (grey bars, N = 4 patients, n = 3) and DD (black bars, N = 4 patients, n = 3)
cells cultured on type-I collagen substrates was assessed using the WST-1 assay.
Data are shown as change scores (absorbance on day 7 minus absorbance on day 1).
Significant effects of treatment vs vehicle are indicated as * p < 0.05 and ** p <
0.01, ns = not significant. Treatments were the following: A) IGFBP-6 treatment
(400 ng/ml) or IGF-II treatment (100 ng/ml) or TGF-β1 (12.5 ng/ml) vs vehicle, B)
IGF-II + IGFBP-6 treatment (100 ng/ml and 400 ng/ml respectively) vs vehicle, and
C) mIGFBP-6 (400 ng/ml) or IGFBP-6 (400 ng/ml) vs vehicle.
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assessed. A single treatment with 12.5 ng/ml of recombinant TGF-β1, as previously
demonstrated [33] in DD and PF (each p < 0.05), and CT (p < 0.01), attenuated
proliferation over the subsequent 7 days relative to vehicle treated cells. To assess the
effects of IGF-II on cellular proliferation, DD, PF and CT cells were treated with a single
dose of recombinant IGF-II at 100 ng/ml, as previously described [34,35]. While
treatment with recombinant IGF-II at 100 ng/ml significantly enhanced CT cell
proliferation over 7 days (p < 0.05), no significant effects of IGF-II treatment on the
proliferation of DD or PF cells were detected (Figure 3-3A). As shown in Figure 3-3B,
co-incubation of cells with IGFBP-6 and IGF-II at equimolar concentrations did not
rescue the inhibitory effects of IGFBP-6 treatment. To confirm IGF-II independence of
these effects on cell proliferation, DD, PF and CT cells were treated with a single dose of
a non-IGF-II binding IGFBP-6 analog (mIGFBP-6) [36] at 400 ng/ml. IGFBP-6 and
mIGFBP-6 had similar inhibitory effects on the proliferation of PF cells (p < 0.05, Figure
3-3C) and CT cells (p < 0.01, data not shown). Unlike in PF and CT cells, mIGFBP-6
was significantly (p < 0.05) less effective at inhibiting DD cell proliferation than IGFBP6, although both treatments had statistically significant negative effects relative to vehicle
treated cells (p < 0.01).

3.3.4

IGF-II enhances DD cell contraction of collagen lattices

To assess the effects of IGF-II and IGFBP-6 on DD and PF cell contractility, we utilized
two types of fibroblast populated collagen lattice assays, relaxed FPCLs (rFPCLs)
[28,37–39] and stressed FPCLs (sFPCLs) [21,40,41]. The 72 h incubation period in the
presence of treatments in the sFPCL protocol allowed us to distinguish the effects of
treatment-induced myofibroblast differentiation [42] from the immediate effects of
treatment that are measured in rFPCLs [38].
DD cells were more contractile than PF cells in rFPCL assays in the absence of treatment
(Figure 3-4A). IGFBP-6 (400 ng/ml) did not significantly affect the contractility of DD,
PF or CT cells in rFPCLs (data not shown). IGF-II (100 ng/ml) significantly enhanced
rFPCL contraction by DD cells (p < 0.05) but did not significantly affect PF (Figure 34A) or CT cell (data not shown) contractility. Platelet derived growth factor (PDGF), an
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established inducer of fibroblast contractility in rFPCLs [38], enhanced both DD and PF
cell contractility in these assays. IGFBP-6 (400 ng/ml) did not significantly affect the
contractility of DD, PF or CT cells in sFPCLs (data not shown). IGF-II treatment
significantly enhanced both PF (p < 0.05) and DD (p < 0.001) cell contractility over 6 h
after lattice release (Figure 3-4C and D respectively). In addition to treatment effects,
significant IGF-II treatment/time interactions were evident for both cell types (p < 0.01).
While IGF-II significantly induced DD cell contraction at all time points after release, the
level of significance increased from p < 0.01 at release to p < 0.001 6 h after release.
Significant effects of IGF-II treatment were only evident 2 h after release in PF cells (p <
0.05). TGF-β1 treatment (12.5 ng/ml) significantly enhanced DD cell (p < 0.01)
contractility in these assays, whereas a significant TGF-β1 treatment/time interaction was
evident in PF cells (p < 0.01) 6 h after lattice release (p < 0.01) (Figure 3-4B). IGF-II did
not significantly affect sFPCL contraction by CT cells (data not shown). Co-treatments
with equimolar IGFBP-6 and IGF-II abrogated the IGF-II induced contractility of both
DD and PF cells (Figure 3-5A).
As TGF-β1 signaling intermediates and IGF-II have been reported to elicit combinatorial
effects on myofibroblast differentiation in murine fibroblasts [43], we assessed the effects
of treating PF and DD cells with both growth factors in combination (Figure 3-5B).
While TGF-β1 and IGF-II treatments significantly enhanced the contractility of PF and
DD cells relative to vehicle treated controls, no significant combinatorial treatment
effects were detected over treatment with either factor in isolation.

3.4

Discussion

In this study, we have identified IGFBP6 and IGF2 as reciprocally dysregulated genes in
DD cells relative to PF cells. Previous studies have reported increased TGF-β1
expression and sensitivity, enhanced contractility, α smooth muscle actin (αSMA)
expression and myofibroblast differentiation in DD cells [44–46], features shared with
primary myofibroblast-like cells derived from other fibroses [47–49]. Other than TGF-β1,
very few of the dysregulated genes in DD cells have been functionally linked to the main
characteristics of DD development, namely fibroblast proliferation and palmar fascia
contraction by myofibroblasts. Based on our findings, we hypothesize that downregulated
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Figure 3-4: IGF-II enhances DD cell contraction of collagen lattices.
The effects of IGF-II on PF (grey bars) and DD (black bars) cell contractility were
assessed in relaxed fibroblast populated collagen lattice assays (rFPCLs) over 24 h
(A) and stressed FPCLs (sFPCLs) over 6 h (B, C and D) as described in the
Methods section. Significant treatment effects are denoted as * p < 0.05, ** p < 0.01
and *** p < 0.001. The effects of treatment vs vehicle on rFPCL contraction were
assessed by t-test analyses at 24 h (N = 4 patients, n = 3). The effects of treatment
vs vehicle on sFPCL contraction were assessed by ANOVA of repeated measures
analyses and, where treatment/time interactions were detected, by simple main
effects analyses (N = 10 patients, n = 3). Treatments were the following: A) IGF-II
(100 ng/ml) or PDGF (100 ng/ml) in rFPCLs and B) IGF-II (100 ng/ml) or TGF-β1
(12.5 ng/ml) in sFPCLs. C) Contraction curves for PF cells from 0.5 h to 6 h after
lattice release with vehicle, TGF-β1 or IGF-II treatment. D) Contraction curves for
DD cells from 0.5 h to 6 h after lattice release with vehicle, TGF-β1 or IGF-II
treatment. Significant treatment/time interactions are denoted as * p < 0.05 and ** p
< 0.01.
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Figure 3-5: IGF-II-induced PF and DD cell contractility is attenuated by
IGFBP-6, but not enhanced by TGF-β1.
The effects of co-treatment with IGF-II and IGFBP-6 (N = 3 patients, n = 3), and
IGF-II and TGF-β1 (N = 6 patients, n = 3) were assessed on PF (grey bars) and DD
(black bars) cell contractility in stressed fibroblast populated collagen lattice assays
(sFPCLs) over 6 h. Significant effects of treatment vs vehicle on sFPCL contraction
were detected by ANOVA of repeated measures analyses. Statistically significant
treatment effects are denoted as * p < 0.05 and *** p < 0.001, ns = not significant.
Treatments were the following: A) IGFBP-6 (400 ng/ml) and IGF-II (100 ng/ml)
and B) TGF-β1 (12.5 ng/ml) and IGF-II (100 ng/ml).
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IGFBP6 expression and upregulated IGF2 expression jointly contribute to DD
progression by promoting fibroblast proliferation, contractility and palmar fascia
contraction in DD.
As IGFBP-6 is a high affinity IGF-II binding protein [23], we hypothesized that
attenuation of IGFBP6 expression and IGFBP-6 protein levels in DD would enhance
IGF-II availability and signaling. IGF-II signaling can promote mitogenesis [50–53] and
inhibit apoptosis [54,55], and IGFBP-6 can antagonize these effects by sequestering and
inhibiting IGF-II signaling [30,56–58]. However, co-treatment with equimolar IGFBP-6
and IGF-II elicited similar negative effects on the net proliferation compared to cells
treated with IGFBP-6 alone. Consistent with these findings, an IGFBP-6 analog with
attenuated IGF-II binding capacity (mIGFBP-6) exhibited similar effects on PF cell
proliferation to native IGFBP-6. These data suggest that IGFBP-6 attenuates PF cell
proliferation through mechanisms that are independent of IGF-II sequestration, consistent
with a subset of reports of IGFBP-6 actions in other diseases [36,59,60]. In contrast to
PF and CT cells, mIGFBP-6 was significantly less effective at decreasing DD cell
proliferation than native IGFBP-6. IGF2 expression is enhanced in DD cells relative to
PF and CT cells, and exogenous IGF-II treatment did not promote DD cell proliferation
(Figure 3-3A). We speculate that increased endogenous IGF-II expression in DD may be
one of the (potentially several) factors that enhance DD cell survival (rather than
proliferation) in a low IGFBP-6 environment. The identification and elucidation of the
IGF-II dependent and independent mechanisms activated by IGFBP-6 in DD cells will be
a focus of future studies.
In contrast to its inhibitory effects on cellular proliferation, IGFBP-6 treatment did not
significantly inhibit cellular contractility. However, IGFBP-6 was effective at attenuating
the increase in PF and DD cell contractility induced by IGF-II treatment (Figure 3-5A).
Overall, our data imply two distinct consequences of IGFBP-6 depletion in DD that are
likely to enhance disease progression; the induction of IGF-II dependent and/or
independent processes that increase the net proliferation of palmar fascia cells, and the
enhancement of IGF-II induced cellular contractility.
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In contrast to a previous study in nodule-derived DD cells cultured on tissue culture
plastic where TGF-β1 was shown to be growth-stimulatory [44], TGF-β1 consistently
inhibited the proliferation of DD, PF and CT cells cultured on type-1 collagen culture
substrates (Figure 3-3A). This may reflect the effects of differing culture substrates
(tissue culture plastic vs type-1 collagen in this study) and/or a biphasic effect of TGF-β1
on fibroblast proliferation that is dose-dependent (0.025 ng/ml vs 12.5 ng/ml in this
study). TGF-β1 concentrations used in this study were based on a previous report in DD
identifying 12.5 ng/ml as the maximum concentration required to induce myofibroblast
formation without having negative inhibitory effects [33]. As enhanced fibroblast
proliferation and myofibroblast differentiation have been previously described as
mutually exclusive outcomes in some fibroblast models [43], and TGF-β1 is an
established inducer of myofibroblast differentiation [42,48], myofibroblast differentiation
may be the dominant phenotype under these culture conditions. The increased TGF-β1
expression and enhanced basal contractility of DD cells [44–46] suggest that DD cells
have differentiated further toward a myofibroblast phenotype than PF cells.
Our analyses of DD and PF cells treated with TGF-β1 or IGF-II revealed some interesting
and distinct behaviors in these genetically matched cells at differing stages of
differentiation. TGF-β1 treatment significantly enhanced DD cell contractility (p < 0.01)
but no significant treatment/time interactions were evident, suggesting that the
procontractile effects of TGF-β1 treatment were induced prior to, and not after, lattice
release. In contrast, no significant TGF-β1 treatment effects on PF cells were detected,
and a significant (p < 0.01) time/treatment interaction was evident, suggesting that most
of the contractility induced by TGF-β1 in PF cells occurred during the lattice contraction
phase after release. These differences are visually evident in the parallel versus divergent
contraction curves in Figure 3-4C and D. In contrast, IGF-II induced treatment and
treatment/time interactions in DD cells, indicating effects of treatment both pre- and postrelease. IGF-II also induced treatment and treatment/time interactions in PF cells;
however simple main effects analyses revealed that IGF-II treatment did not significantly
affect lattice contraction until 2 h after release. These data suggest that IGF-II can act
both pre- and post-release to enhance DD contraction, while acting mostly post-release to
increase PF cell contraction. Thus, IGF-II and TGF-β1 may activate or potentiate distinct
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pro-contractile signaling pathways in DD and PF cells. We were unable to detect
significant additive effects of TGF-β1 and IGF-II treatment in our analyses; however it is
unclear if that is because the pro-contractility pathway(s) were fully activated by each
factor in isolation or if our assays were too insensitive to detect modest additive effects of
treatment in cells with enhanced levels of contractility.
The molecular mechanisms activated by IGF-II to enhance the contractility of DD and PF
cells are currently unclear. Consistent with their contractile myofibroblast-like
phenotype, untreated DD cells contracted rFPCLs to a greater extent than PF cells over
24 h. DD cell contraction of rFPCLs was significantly (p < 0.05) enhanced by IGF-II,
whereas PF cells were insensitive to IGF-II treatment under identical conditions. These
data suggest that IGF-II can induce lattice contraction by DD cells without modifying the
differentiation state of these cells, a process that typically requires a 48–72 h preincubation period under isometric tension. We speculate that IGF-II enhances the threedimensional migration of DD cells in these rFPCLs, an effect previously shown for
normal fibroblasts treated with PDGF [33]. PDGF treatment significantly enhanced
rFPCL contraction by both DD (p < 0.01) and PF (p < 0.05) cells (Figure 3-4A), whereas
TGF-β1, which significantly enhanced DD cell contraction in sFPCLs (Figure 3-4B), had
no discernible effects on the contractility of DD or PF cells in rFPCLs (data not shown).
That IGF-II enhanced rFPCL contraction by DD cells but not PF cells suggests that DD
cells have enhanced sensitivity to IGF-II signaling, and that there may be a functional
link between IGF-II sensitivity and the differentiation state of these cells. If future studies
are able to substantiate this link, local administration of IGF signaling inhibitors [61–63]
may have utility as novel treatment approaches to attenuate the contractility of
myofibroblasts in DD patients post-surgery. Alternatively, novel therapies that restore
IGFBP-6 levels to those evident in normal palmar fascia may be sufficient to attenuate
IGF-II signaling and myofibroblast contractility.
IGFBP-6 attenuated DD proliferation, while exogenous IGF-II potently enhanced the
contractility of DD cells. Future studies will focus on elucidating the IGF-II-independent
mechanisms regulated by IGFBP-6 and the mechanisms by which IGF-II signaling
enhances DD cell contractility. These findings implicate IGFBP-6 and IGF-II as novel

90

regulators of DD cell proliferation and contractility that may have utility as targets to
inhibit DD progression and recurrence. Additionally, these results support our hypothesis
that the attenuation of IGFBP6 expression and enhancement of IGF2 expression promote
DD development. Investigation into the molecular mechanisms that increase IGF2
expression in DD will be the subject of chapter 4.
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Chapter 4

4

An analysis of transcriptional dysregulation of IGF2
expression in Dupuytren’s Disease
4.1

Introduction

The Insulin-like Growth Factor (IGF) family is comprised of 2 ligands, IGF-I and –II, 6
high affinity binding proteins (IGFBP-1 to -6) and 2 receptors, the Type I and Type II
IGF receptors [1]. IGFBPs regulate the bioavailability of their ligands to their signalling
receptor, the Type I IGF receptor (IGFIR) [1–3]. The Type II IGF Receptor (IGFIIR),
which is also a cation-independent mannose-6-phosphate receptor, is a negative regulator
of IGF-II signalling in most tissues. The IGFIIR can internalize IGF-II, and molecules
with a mannose-6-phosphate moiety, for lysosomal degradation [4].
IGF signalling through the IGFIR can regulate proliferation, differentiation, and survival
in a variety of systems (reviewed in [5,6]). As their names suggest, IGFs can also signal
through the insulin receptor (InsR) to elicit metabolic or proliferative effects (reviewed in
[7]). While isoform B of InsR has much higher affinity for insulin than for either IGF,
IGF-II can interact with the isoform A of the InsR, (which lacks exon 11) with high
affinity at physiologically relevant concentrations [8]. Additionally, subunits of IGFIR
and InsR can create heterodimers and act as an additional set of signalling receptors for
IGFs and insulin [9]. A key difference between the two IGFs is that IGF-I is largely
regulated by growth hormone [10,11] while IGF-II is largely growth hormone
independent and subject to multiple layers of complex genomic regulation and processing
instead [12]. IGF-II levels are at their highest in the fetus, where it is believed to play an
integral role in embryonic development [13–16]. Following birth, IGF-II levels decline
and then increase again in adult humans until IGF-II becomes the predominant IGF in the
circulation [14].
The gene that encodes IGF-II, IGF2, is located within a 30 kb DNA region on
chromosome 11p15.5. This gene contains 10 exons and can be transcribed from 4 distinct
promoters; however the functional peptide is only encoded by the last 3 exons [17].
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Unlike most autosomal genes, which are expressed or transcriptionally silent irrespective
of the parent from which they were derived, IGF2 is genomically imprinted and
expressed only from the paternally-derived allele in most mammalian tissues [18]. Like
many imprinted genes, IGF2 is located within a “cluster” of other genes that are also
imprinted in various tissues. IGF2 is located adjacent to the insulin gene, INS, which is
imprinted in yolk sack [19], and H19 [20]. H19 encodes a non-coding RNA that is
reciprocally expressed with IGF2 i.e. H19 is only expressed from the maternally derived
allele in most mammalian tissues [20]. IGF2 and H19 are separated by a CG-rich motif
known as the H19 imprinting control region (ICR). In tissues where IGF2 is imprinted,
the H19 ICR is methylated on the paternally derived allele and unmethylated on the
maternally derived allele. ICR methylation prevents CCCTC binding factor (CTCF)
interactions and maintains transcriptional silencing of H19 by allowing transcriptional
enhancers to drive IGF2 expression [21,22]. In addition to being regulated by the H19
ICR, IGF2 contains another differentially methylated region (DMR) that is unmethylated
on the paternally derived allele where IGF2 is expressed. The H19 ICR is unmethylated
on the maternally derived allele, allowing CTCF to bind and prevent transcriptional
enhancers from activating IGF2 expression [21,23]. The IGF2 DMR is methylated on the
maternally derived allele and is believed to act as an additional mechanism to prevent
IGF2 transcription from this allele (Figure 4-1).
In Wilm’s tumour [24] or other cancers [25], the imprinting control mechanism can be
disrupted and IGF2 can be expressed from both alleles. This is usually, but not
exclusively, associated with loss of H19 expression from both alleles [26]. Unlike most
tissues, IGF2 is biallelically expressed in adult human liver and in some areas of the brain
[27,28]. The biological significance of genomic imprinting of genes in some tissues and
not in others is still being elucidated.
In addition to its transcriptional regulation by imprinting, tissue-specific regulation of
IGF2 transcription can be imposed by the use of any or all of 4 distinct promoter regions
designated P1, P2, P3, and P4 [17]. Transcription from these promoters can result in up
to 5 distinct IGF2 mRNA transcripts, each of which encodes the same peptide [17]. In
adult humans, transcription from P2 – P4 varies between subsets of tissue or organs, and
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Figure 4-1: Allele-specific human IGF2 and H19 gene map
The human IGF2 gene is genomically imprinted and reciprocally expressed with the
maternally expressed H19 gene, which encodes a non-coding RNA. On the paternal
allele, the IGF2 differentially methylated region (IGF2 DMR) is unmethylated while the
H19 imprinting control region (H19 ICR) is methylated. Methylation of the H19 ICR
prevents CTCF from binding, and allows enhancer elements to initiate IGF2 expression.
On the maternal allele, the H19 ICR is unmethylated allowing CTCF to bind and block
enhancer activity. This prevents IGF2 expression from the maternally-derived allele.
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P3 and P4 appear to be the most active [17,29,30]. P1 transcripts are usually associated
with the subset of tissues that biallelically express IGF2, such as the liver and some parts
of the brain [27,31], while P2 transcripts have been shown to be associated with
transformed or neoplastic cells [30]. The increased expression of IGF2 in some cancers
can be the result of multiple promoter usage that results in multiple IGF2 transcripts, or
the enhanced activity of individual promoters. For example, the P3 promoter is
hypomethylated in a subset of human osteosarcomas and results in increased IGF2
transcripts from P3 [32], while imprinting is lost (LOI) in other osteosarcoma cells [24]
and IGF2 is expressed from several promoters on both alleles [29]. The potential for
additional and/or enhanced IGF2 promoter usage contributing to increased IGF2 mRNA
levels in benign fibrosis such as Dupuytren’s disease (DD) has not been reported.

4.1.1

Dupuytren’s Disease

DD is a benign fibromatosis affecting the palmar fascia that is characterized by the
development of permanent finger contractures. The palmar fascia thickens and hardens as
the result of excess collagen deposition by fibroblasts and contractile myofibroblasts
within the disease cord [33–35]. This fibroproliferative disorder is one of the most
common inherited connective tissue disorders affecting Caucasian males over 60 years
[36,37] and there is a lack of truly effective treatment options. The “gold standard”
treatment option, surgical resection of the disease cord [38,39], is associated with
extensive post-operative rehabilitation and at least 1 in 3 patients will experience
recurrence of contractures [40]. There is an obvious need for a better understanding of the
molecular mechanisms that drive Dupuytren’s Disease development so that more
effective and non-surgical therapeutic alternatives can be made available to these
patients.
Like virtually all fibroses, DD is characterized by excessive fibroproliferation, the
increased presence and persistence of contractile myofibroblasts, and excess collagen
deposition [41]. While relatively little is known about the roles of IGF-II in fibrosis
development, it has been shown to induce collagen expression in systemic sclerosisassociated pulmonary fibrosis [42] and to increase the contractility of DD cells [43].
IGF2 expression is also increased in DD cells relative to fibroblasts derived from non-
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fibrotic palmar fascia whereas IGF1 expression is unaffected [43]. The mechanisms that
induce increased IGF2 expression in DD have not yet been investigated.

4.2
4.2.1

Materials and Methods
Sample Collection: tissue and cells

Surgeons at the Roth | McFarlane Hand and Upper Limb clinic resected small palmar
fascia tissue samples from patients with Dupuytren’s Disease (DD) and from patients
undergoing carpal tunnel release (CT) with the approval from the University of Western
Ontario Research Ethics Board for Health Sciences Research involving Human Subjects
(HSREB protocol # 08222E, Appendix C). An additional tissue sample was taken from
Dupuytren’s Disease patients as adjacent, phenotypically normal palmar fascia (PF). All
three samples were also cultured for primary fibroblasts. Patients signed consent forms,
received a letter of information prior to surgery, and their samples were de-identified to
ensure patient confidentiality.

4.2.2

Primary cell culture

Primary fibroblasts were grown for a week in alpha-minimum essential media (α-MEM)
containing 10% fetal bovine serum (FBS), 1% antibiotic-antimycotic and 1% LGlutamine (all from Invitrogen Corporation, Carlsbad, CA) (growth media). Cells were
passaged by first rinsing with 5 ml of phosphate buffered saline (PBS), and then
incubating them with 2 ml 0.05% trypsin-EDTA (Invitrogen Corporation, Carlsbad, CA)
at 37°C for 5 minutes to allow the cells to detach from the surface. Inactivation of the
trypsin was accomplished by adding 2 ml of growth media with FBS. Cells, media and
trypsin were then collected into a 15 ml conical tube by centrifugation (Hettich
Zentrifugen Universal 32) at 2000 rpm for 5 minutes. The supernatant was then aspirated
and the pellet was resuspended in 6 ml of media, split, and fresh growth media was
added. The dishes were then incubated for 3-5 days. Fibroblasts were assessed up to a
maximum of 6 passages.
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4.2.3

RNA isolation and Real Time PCR

Total RNA samples were isolated from primary DD, PF and CT cells using the RNeasy
Mini Kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer’s protocol.
The quality and concentration of RNA were assessed on a NanoDrop Spectrophotometer
ND-1000 (Thermo Scientific, Waltham, MA). cDNA was made from 2 μg of high quality
total RNA using the High-Capacity cDNA Archive Kit (Life Technologies, Burlington,
ON, Canada) in accordance with the manufacturer's instructions. TaqMan gene
expression assays were used to measure IGF2 (Hs01005963_m1) and H19
(Hs00262142_g1) expressions relative to the RPLP0 endogenous control
(Hs99999902_m1) after validation of parallel PCR amplification efficiencies. PCR
reactions employing the ΔΔCT method were carried out under the following conditions:
Initial denaturation at 95 °C for 5 min followed by cycles of denaturation (95 °C for 15
s), primer annealing (60 °C for 1 min) and transcript extension (50 °C for 2 min) for 45
cycles on a Real-Time PCR ABI Prism 7500.

4.2.4

Loss of imprinted expression

Loss of imprinting (LOI) was assessed using nested PCR as described previously [24,44].
Genomic DNA was isolated from patient-derived fibroblasts using the DNeasy Blood and
Tissue Kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer’s
instructions. The DNA samples were screened for heterozygosity of a restriction
fragment length polymorphism (RFLP) in the 3’ untranslated region of the IGF2 gene
which creates an ApaI restriction enzyme site. The first round of PCR with primers PA
and PC was performed on 20-50 ng of genomic DNA and the amplified products were
used as the template for a second round of PCR using primers PB and PC. The PCR
amplicon from the second PCR round was subjected to restriction digestion with ApaI
(New England Biolabs, Whitby, ON, Canada) at room temperature overnight. Primer
sequences were: PA: 5’ TCCTGGAGACGTACTGTGCTA-3’, PB: 5’CTTGGACTTTGAGTCAAATTGG-3’ and PC: 5’-GGTCGTGCCAATTACATTTCA3’ based on previous studies [24,44]. The positions of the primers are depicted in Figure
4-2. Cells were deemed “informative” if they were heterozygous for the ApaI
polymorphism and their alleles could be distinguished by agarose gel electrophoresis.
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Total RNA was isolated from informative patient-derived cells using the RNase-free
DNase set with the RNeasy Mini kit (Qiagen, Mississauga, ON, Canada) in order to
avoid genomic DNA contamination. First-strand cDNA was synthesized using
Superscript II RT (Invitrogen Corporation, Carlsbad, CA) according to the
manufacturer’s protocol with 500 ng of total RNA using the PC primer. The nested PCR
protocol and restriction enzyme digest analyses described from genomic DNA samples
was repeated on ~50 ng cDNA from these cells and a reverse transcriptase negative
control was included to detect any chromosomal DNA contamination.

4.2.5

IGF2 Promoter Usage

The protocol for identifying specific IGF2 promoter usage was adapted from Grbesa et
al. [29]. Promoter-specific primers were used to amplify reverse-transcribed RNA
(cDNA) immediately downstream of specific IGF2 promoters in DD, PF and CT cells.
Primers are listed in Table 4-1 and locations in Figure 4-2. The reverse primer (PR) was
common to all promoter-specific forward primers. Touchdown PCR was carried out with
initial denaturation at 95°C for 5 min followed by 4 cycles of 95°C for 30 s, 68°C for 1
min and 72°C for 1 min, then again for 13 cycles except the annealing temperature
decreased by 1°C each cycle from 68°C, followed by 25 cycles of 95°C for 30 s, 55°C for
1 min and 72°C for 1 min, with the final extension at 72°C for 10 min in the Px2 Thermal
Cycler (Thermo Scientific, Waltham, MA).
Table 4-1: Primers used during touchdown PCR to determine IGF2 promoter usage
in DD, PF and CT cells. The reverse primer was common to all 4 promoter-specific
PCR reactions.
Promoter
P1
P2
P3
P4
PR (reverse)

Primer (5’to 3’)
CGAATTCTGGGCACCAGTGACTCCCCG
ACCGGGCATTGCCCCCAGTCTCC
CGTCGCACATTCGGCCCCCGCGACT
TCCTCCTCCTCCTGCCCCAGCG
CAAGAAGGTGAGAAGCACCAGCAT

Expected Band Size
376 bp
254 bp
186 bp
134 bp
--
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Figure 4-2: Primer map for IGF2 gene
Primer map depicting position of primers used for promoter usage analysis (P1P4, PR) and loss of allele-specific expression (PA, PB, PC). There are 4 distinct
promoters that can initiate transcription of the IGF2 gene. The ApaI restriction
fragment length polymorphism used for the loss of allele-specific expression
analyses is located in the 3’ untranslated region.
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4.2.6

Epigenetic effects on IGF2 expression

DD, PF and CT cells were cultured on type I rat tail collagen (~1.8 mg/ml stock
concentration) to better replicate in vivo conditions. Neutralization solution (3 parts 10X
Waymouth media (Sigma Aldrich, St. Louis, MO), 2 parts 0.34 M NaOH) was added to
the collagen solution in a 1:4 ratio and 1 ml of this solution was added to coat the bottom
of each well in a 6-well tray. The collagen was allowed to set in these trays at 37°C for 30
min. 1x105 cells were seeded in each well of the collagen-coated tray and grown for 2
days in growth media. After 2 days, cells were rinsed twice in PBS and incubated with
serum-free media overnight. Treatments were added to media containing 2% FBS, and
incubated at 37°C with 5% CO2. Each day, fresh media, containing new inhibitor was
added until each treatment regime was completed. Treatments were as follows:
decitabine, a DNA methyltransferase (DNMT) inhibitor (Cedarlane, Burlington, ON,
Canada) was used at 10 µM for 72 hrs and trichostatin A (TSA), a histone deacetylase
inhibitor (Cedarlane, Burlington, ON, Canada) was used at 300 nM for 48 hrs. Cells were
then washed in PBS and incubated with 1 mL of 0.25 mg/ml collagenase XI (Sigma
Aldrich, St. Louis, MO) in Hank’s Balanced Salt Solution media (Sigma Aldrich, St.
Louis, MO) at 37°C for 25 min with rocking. Once the cells were detached, the trays
were placed on ice to inactivate the collagenase. The cells were collected and centrifuged
(Hettich Zentrifugen Universal 32) at 2000 rpm for 5 minutes. The supernatant was
removed, and the pellet was rinsed in 1X PBS and stored at -20ºC prior to RNA isolation
and subsequent real-time PCR analysis of IGF2 and H19 expression. Experiments were
performed on 4 patients (N = 4, n = 1). Paired t tests were used to determine significant
changes in IGF2 or H19 expression when p < 0.05.

4.3
4.3.1

Results
Loss of imprinting in Dupuytren’s Disease cells

IGF2 expression is increased in primary DD fibroblasts relative to controls, but the
mechanisms involved in this induction are currently unknown. Loss of imprinting (LOI)
results in biallelic expression and increased IGF2 transcript levels in cancers; however
there is no evidence of LOI expression of IGF2 in benign fibroses to our knowledge. To
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assess IGF2 imprinting, DD, PF and CT cells were screened to determine whether they
were “informative” for these analyses. The 3’ untranslated region (3’UTR) of the IGF2
gene contains a restriction fragment length polymorphism (RFLP) that introduces an
ApaI restriction enzyme site. An ApaI restriction digest of genomic DNA amplified from
the IGF2 3’UTR allowed for the identification of individuals with one or more of these
RFLPs. In those individuals with an RFLP in only one allele (deemed “informative”), the
two alleles could be distinguished by restriction digest analyses with ApaI and routine
agarose gel electrophoresis. If normal IGF2 imprinting is occurring, only one of these
alleles (with or without the RFLP) will be identified in cDNA derived from reverse
transcribed mRNA. If IGF2 imprinting is lost and both alleles are transcribed, restriction
mapping of cDNA derived from reverse transcribed mRNA is predicted to yield two
DNA species, one with and one without an ApaI restriction site.
Eight PF/DD (N = 8, n = 1) and 7 CT patients (N = 7, n = 1) were screened for
heterozygosity of the IGF2 alleles. 3 PF/DD patients (#188, #265 and #274) were found
to be informative based on the presence of two bands after the ApaI restriction digest of
the IGF2 3’UTR PCR product derived from the genomic DNA by agarose gel
electrophoresis (Figure 4-3A). Unfortunately, none of the 7 CT patient cell lines were
informative (data not shown), with 4/7 containing- and 3/7 lacking the polymorphic ApaI
site in both alleles. When mRNA samples derived from the informative DD cell lines
were reverse transcribed into cDNA, 2 of the 3 informative patient samples yielded
restriction patterns similar to their genomic DNA samples, indicating loss of IGF2
imprinting. Restriction digest analysis of cDNA derived from patient #274 yielded a
single band indicating the expression of a single allele that lacked an ApaI restriction site.
Interestingly, evidence of LOI of IGF2 was also evident in the PF cells derived from
patients #188 and #265, whereas maintenance of IGF2 imprinting was evident in PF cells
derived from patient #274 (Figure 4-3B).
Biallelic expression of IGF2 or LOI at the IGF2 locus is usually associated with a
reciprocal loss of H19 expression [26]. To assess this in DD, IGF2 and H19 mRNA
levels were assessed by real-time PCR in the 3 informative patients identified in the LOI
studies. Consistent with previous analyses, all 3 DD cell lines exhibited higher IGF2
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Figure 4-3: Loss of imprinting at the IGF2 locus is detected in DD cells.
A) Genomic DNA samples from fibroblasts derived from patients with DD were
screened for heterozygosity of an ApaI restriction site in the 3’ UTR of the IGF2
gene by PCR. U = uncut DNA, C = restriction digested with ApaI. Three patients
(*, #188, #265 and #274) were found to be “informative” as indicated by the
presence of two bands in the “C” lane (orange arrows) corresponding to one allele
with and one without an ApaI restriction site. B) Reverse transcribed mRNA
(cDNA) of these 3 patient-derived cells were analyzed by PCR to determine
whether ApaI restriction digests of this region in IGF2 gene resulted in 2 bands
(confirming LOI) or a single band (maintenance of imprinting). C) QPCR
analysis of IGF2 and D) H19 expression in PF (grey bars) and DD (black bars)
cells derived from the 3 informative patients (N = 3, n = 1)
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expression than their corresponding PF cells (Figure 4-3C). H19 expression was
undetectable after 45 PCR cycles in the DD cells derived from the two patients which
displayed loss of imprinting (#188 and #265), indicating that the H19 transcript levels
were either absent or below detectable limits (Figure 4-3D). In contrast, H19 mRNA was
readily detectable in DD cells derived from patient #274, consistent with maintenance of
normal IGF2/H19 imprinting. In comparison to DD cells derived from the same patients,
H19 expression was readily detectable in all three sets of PF cells.

4.3.2

Histone deacetylase and DNA methyltransferase inhibitors
increases IGF2 and H19 expression, respectively

Previous reports have shown that histone deacetylases (HDACs) regulate many imprinted
genes, including IGF2 in human fibroblasts [45]. To determine if HDACs and other
epigenetic modifiers were having distinct effects in PF and DD cells, the effects of broad
spectrum inhibitors of HDACs and DNA methyltransferases (DNMTs) on IGF2 and H19
expression were assessed. Trichostatin A, an established HDAC inhibitor [46,47], was
shown to significantly induce IGF2 expression (Figure 4-4A) and in PF (p < 0.05) and
DD (p < 0.01) cells, and significantly attenuate H19 expression (Figure 4-4B) in PF cells
(p < 0.01), relative to vehicle treatment. Decitabine, an established DNMT inhibitor [48],
induced H19 expression (Figure 4-4B) in PF cells (p < 0.05) only.

4.3.3

Multiple promoters are active in Dupuytren’s Disease

IGF2 transcripts can be derived from 4 different promoters (P1-P4) and their activities
are reported to vary with tissue type, developmental stage and disease state [17,27,49].
To identify the IGF2 promoters that were active in DD, PF and CT cells, promoterspecific primers were designed based on previous studies [29] and the expression levels
of promoter-specific transcripts were assessed by qualitative reverse transcription PCR.
RNA transcribed from HepG2 cells was used as a positive control for these analyses.
Unexpectedly, despite P1 activity normally being highest in the liver [27], P1 transcripts
were not detected in these liver carcinoma cells, which is in accordance with a previous
study reporting that IGF2-P1 is silent in HepG2 cells [50]. As shown in Figure 4-5, IGF2
transcripts from P3 and P4 were consistently expressed in all of the DD, PF and CT cell
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Figure 4-4: Inhibition of histone deacetylases induces IGF2 expression in DD
and PF cells and attenuates H19 expression in PF cells.
The effects of trichostatin A (TSA, 300 nM for 48 hrs), a histone deacetylase
inhibitor, and decitabine (Dec, 10 uM for 72 hrs), a DNA methyltransferase inhibitor
were assessed on A) IGF2 and B) H19 expression in PF (grey bars) and DD cells
(black bars) cultured on type I collagen (N = 4, n = 1). Treatment were refreshed each
day in media containing 2% FBS. Significant treatment effects were determined by
paired t test and are denoted as * p < 0.05 and ** p < 0.01. (Data is plotted as mean ±
SE)
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Figure 4-5: DD cells express IGF2 transcripts derived from P2, P3 and P4.
PCR analysis of A) P1, B) P2, C) P3 and D) P4 promoter-derived IGF2 transcripts in
primary DD, PF and CT cells (N = 4 each, n =1) . Reverse transcribed RNA from HepG2
cells was used as a positive control in this analysis. As shown in A) IGF2 transcripts
originating at P1 were only evident in 2 PF cells isolates. B) IGF2 transcripts originating
at P2 were evident in a subset of DD, PF and CT cells. In contrast, IGF2 transcripts
originating at P3 (C) and P4 (D) were evident in all 3 cell types. (* denotes patient
identified to display loss of imprinting).
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lines assessed (N = 4/group, n = 1). In contrast, 3/4 of the DD cells, 2/4 of the PF cells
and 1/4 of the CT cells utilized P2 to transcribe IGF2. Transcripts from P1 were
identified in 2/4 PF patients (including patient #265, identified to have LOI of IGF2)
whereas no evidence of P1 activity was evident in any of the DD or CT cell lines
assessed.

4.4

Discussion

In this study, loss of imprinted IGF2 expression and aberrant IGF2 promoter usage were
investigated as possible explanations for the increased IGF2 expression in DD. Loss of
imprinting was detected in a subset of DD patients and multiple IGF2 promoters were
activated in DD cells, both of which are likely to contribute to the increased IGF2
expression in DD cells. Loss of imprinting of IGF2 has been demonstrated in a variety of
cancers [24] and the functional consequences of this are typically: increased IGF2
expression and cell proliferation [51,52], presumably due to increased IGF-II signalling.
LOI of IGF2 was detected in two of the three “informative” patients with Dupuytren’s
Disease identified in this pilot study. Many more informative patients would need to be
identified to gain further insight into how prevalent LOI of IGF2 is in DD.
Interestingly, LOI of IGF2 was also detected in PF cells derived from the non-fibrotic
palmar fascia of these patients. While the palmar fascia from which PF cells are derived
is phenotypically normal, it is immediately adjacent to fibrotic DD cord tissue and may
be in an activated “pre-disease state”. Genetic predisposition to DD development is also
evident in many patient families, and thus PF cells may be predisposed to fibrosis relative
to normal palmar fascia fibroblasts (CT cells). These PF cells exhibited LOI of IGF2 but
maintained detectable H19 expression, unlike the DD cells derived from these patients.
While preliminary, these data may be suggestive of progressive changes in the IGF2/H19
axis during disease development. Additional studies will be necessary to determine if
loss of IGF2 imprinting precedes loss of H19 expression during DD development.
The proportion of the population that are heterozygous for the ApaI polymorphism in the
3’UTR of IGF2 was reported to be ~44% [53], which correlates well with our findings of
37.5% of DD patients being heterozygous for this RFLP. 62.5% of DD patients and 57%
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of CT patients were homozygous for the ApaI polymorphism, which is higher than the
48.3% reported in larger population studies [53]. In contrast to CT patients, none of the
DD patients that were screened in this analysis lacked the RFLP, a genotype which is
reported to represent only ~8% of the population [53]. Taking all cell groups together, of
the 15 patients screened for heterozygosity of the ApaI polymorphism, 20% were
heterozygous, 60% were homozygous for the site, while 20% lacked the polymorphism.
While the different frequencies of the genotypes observed in this study are likely to be
skewed by the small sample size, it is also plausible that the frequencies differ between
disease and normal populations. Larger scale studies would be required to establish more
accurate genotype frequencies within Dupuytren’s Disease populations relative to
normal.
Since no heterozygous (informative) CT patients were identified in this study, no
conclusions can be drawn in the context of a “baseline” for LOI of IGF2 in the normal
population. Previous studies have indicated that 20 to 25% of Caucasians with a mean
age of 60 years demonstrate LOI of IGF2 [54]. LOI of IGF2 may be inherited or
congenitally acquired and be stable over time in these patients [54]. It is unclear if the
findings of this study, indicating LOI of IGF2 in 2/3 informative patients, indicate chance
findings or if LOI of IGF2 is a risk factor for DD development. Additional, much larger
scale studies will be required to address these possibilities.
The use of IGF2 promoter P1was identified in 50% of the PF cells assessed in this study,
but not in any of the DD or CT cells assessed. P1 transcripts are normally evident in the
liver and in those parts of the brain where biallelic expression of IGF2 is the norm. Two
of the four patients from whom these PF cells were derived also demonstrated LOI of
IGF2, however only one expressed P1 transcripts. These P1 transcripts were expressed in
PF cells, but not in DD cells derived from the same patients with increased IGF2
expression. This is not the first study in which the presence of IGF2 transcripts from P1
has failed to correlate with LOI of IGF2 [29] and further analyses will be required to
determine the relevance of these findings.
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Further studies will be required to gain a better understanding of LOI of IGF2 in DD.
These studies should include investigations of CCCTC binding factor (CTCF)
interactions with the H19 imprinting control region (ICR), assessments of the methylation
status of the H19 ICR and of the IGF2 differentially methylated region (DMR).
Methylation at the H19 ICR would prevent CTCF from binding and allow enhancers to
activate IGF2 expression while silencing H19. The current dogma would predict that the
H19 ICR will be methylated in patients demonstrating LOI of IGF2 while the IGF2 DMR
may be unmethylated. Previous studies in other systems would suggest that the
methylation status of these loci are integral to maintaining imprinting at the IGF2-H19
axis [21,26,55]. The addition of a DNMT inhibitor to PF cells significantly increased H19
expression and a non-significant trend (p = 0.123) towards increased H19 expression was
evident in DD cells. These findings are consistent with hypomethylation of the H19 ICR,
which allows CTCF to bind and activate H19 transcription. Unexpectedly, treatment of
DD and PF cells with the DNMT inhibitor had no discernible effects on IGF2 expression.
Based on previous studies [56,57], decitabine (5-aza-2-deoxy-cytidine) treatment was
predicted to initiate expression of IGF2 from the maternal allele and to potentially
increase P2-P4 promoter usage. One possible explanation is that decitabine only inhibits
DNA methylation in newly replicated DNA [48]. Thus, it may be necessary to treat cells
over a multiple passages to induce the increases in IGF2 expression reported in other
systems [57]. As P2 was activated more frequently in DD cells, it is possible that the
IGF2-P2 promoters are in a less methylated state in these cells relative to the same sites
in CT cells. Future studies should focus on determining the relative methylation status of
the P2 and P3 promoter regions in DD, PF and CT cells.
Histone acetylation is an epigenetic mark that promotes opening of the chromatin
structure and the activation of gene transcription [58]. Trichostatin A (TSA) has been
shown to inhibit histone deacetylases (HDACs), the enzymes that inhibit gene
transcription by removing these acetylation marks [46,47]. HDACs can regulate
imprinted genes in human fibroblasts and HDAC inhibition by TSA has been previously
demonstrated to induce LOI of IGF2 [45]. TSA treatment of PF and DD cells increased
IGF2 expression in both groups, suggesting that histone acetylation is likely to have a
role in regulating IGF2 gene expression in these cells. Future studies could confirm
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whether HDAC inhibition increased IGF2 expression in PF and DD cells by inducing
biallelic IGF2 expression.
Both loss of imprinting and activation of the IGF2-P2 promoter are likely to contribute to
the increased IGF2 expression evident in DD cells. This increase in IGF2 expression is
predicted to cause increased IGF-II signalling and promote the contractility of DD cells.
IGF-II inhibitors or factors that regulate IGF2 expression may have potential as
therapeutic targets to attenuate DD progression and recurrence. Additionally, if loss of
imprinting is confirmed to be a relatively common component of DD development,
biallelic IGF2 expression may have utility as one of several markers to differentiate
between the general population and those individuals who are predisposed to develop
Dupuytren’s Disease.
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Chapter 5

5

General Discussion and Conclusion
5.1

Thesis Summary

Dupuytren’s Disease (DD) is a heritable and benign fibromatosis that affects the palmar
fascia. While the name specifically refers to contractile fibrosis of this particular tissue,
this disease displays characteristics that are common to other connective tissue fibroses
[1]. Two of these characteristics are increased β-catenin levels and the repressed
expression of IGFBP6. In chapter 2 of this thesis, β-catenin was shown to associate with
the promoter region of IGFBP6 in PF and CT cells, which are derived from non-fibrotic
tissues, but not fibrosis-derived DD cells. These findings correlated with increased
IGFBP6 expression levels in PF and CT cells relative to DD cells and were consistent
with causative link between loss of β-catenin interactions with the IGFBP6 promoter and
IGFBP6 expression. In addition to IGFBP6, more than 2 000 additional and novel genes
were identified that have interactions with β-catenin that were specific to DD, PF or CT
cells.
In chapter 3, the functional consequences of depleting IGFBP6 expression was examined
in the contexts of cellular proliferation, contractility and migration. Exogenous addition
of IGFBP-6 was shown to inhibit the proliferation of DD, PF and CT cells. The major
IGFBP-6 ligand, IGF-II, was found to be upregulated in DD, and distinct functional roles
for this peptide were identified in CT, PF and DD cells. These novel roles included IGFII induced increases in the cellular contractility and migration of DD cells, increased
contractility of PF cells and increased proliferation of CT cells.
Lastly, the mechanisms that promote the overexpression of IGF2 in DD cells were
explored in chapter 4. Loss of IGF2 imprinting was identified in a subset of DD patients,
and cell-type specific aberrations in IGF2 promoter usage were identified in DD, PF and
CT cells. The findings reported in Chapters 2, 3 and 4 suggest that a complex array of
transcriptional modifications and signalling events promote DD development. Some of
these events can be envisaged as contributing to a potential feedback loop, where loss of
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β-catenin interactions with the IGFBP6 promoter region in DD cells leads to
downregulation of IGFBP6 expression and IGFBP-6 secretion, thereby enhancing IGF-II
signalling, contraction of ECM by DD cells and, based on previous literature [2,3], IGFII and mechano-transduction induced changes in the accumulation of β-catenin in palmar
fascia fibroblasts.

5.2

Dupuytren’s Disease and cancer development

The previous studies from our laboratory that identified β-catenin accumulation in DD
cells [4] correlated with the increased levels of β-catenin interactions with the genome in
DD cells relative to CT and PF cells reported in this thesis. In addition to the findings
discussed in detail in Chapter 2, the Ingenuity analysis revealed that many of the genes
specifically associated with β-catenin in DD cells have been previously reported to have
roles in cancer development. These findings may have relevance to the increased
incidence of cancer development in patients with a history of DD [5–7]. Correlations
between types of abnormal wound repair including fibrosis and cancer development have
been extensively reviewed in the literature [8], and there is evidence that some of the
molecular mechanisms that promote fibrosis can lead to cancer development [9,10]. The
stroma microenvironment around epithelial tumours has many similarities to the
extracellular matrix in fibrosis, including the increased deposition of collagens and other
ECM molecules, and these changes have been correlated with increased cancer risk [11–
13] and enhanced myofibroblast differentiation [14].
The findings of loss of IGF2 imprinting and aberrant IGF2 promoter usage in DD and PF
cells described in Chapter 4 may provide additional insights into the links between DD
and tumour development. Loss of IGF2 imprinting is a relatively common occurrence in
cancers and has been implicated in tumour development [15–17]. While loss of IGF2
imprinting is associated with overgrowth syndromes [18], a subset of the apparently
normal population can also exhibit loss of IGF2 imprinting in some tissues [19]. It is
unclear whether these individuals are predisposed to cancer development, and/or from the
findings in Chapter 4, DD development relative to the majority of the population
exhibiting normal IGF2 imprinting. Much larger scale studies will be required to
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determine if loss of IGF2 imprinting is over-represented in a subset of patients with DD,
and if so, if those patients have an increased incidence of cancer development.

5.3

Origin of DD myofibroblasts

Cancer-associated fibroblasts (CAFs) have been shown to enhance epithelialmesenchymal transition (EMT) and tumour progression by releasing growth factors and
cytokines into the stroma [20,21]. β-catenin-mediated trans-regulation of gene
transcription has a well-documented role in promoting EMT [2,22–24], and IGF-II is one
of the growth factors shown to induce β-catenin nuclear translocation and EMT [2]. It is
plausible that keratinocytes from the epidermis or endothelial cells from adjacent blood
vessels may undergo epithelial or endothelial transition to fibroblasts or myofibroblasts
(Figure 5-1) to promote DD progression. DD-associated fibroblasts have been shown to
secrete factors, such as TGF-β, IGF-II and EGF, with established roles in promoting
EMT through β-catenin-mediated processes [2,25–28]. As shown in Figure 5-2, TGF-β
can downregulate IGFBP6 expression and IGFBP-6 secretion, effects that are predicted
to increase IGF-II signalling. Increased IGF-II signalling may promote nuclear
translocation of β-catenin and facilitate EMT in DD. TGF-β signalling can also increase
β-catenin levels in DD [3], however whether this increase in total cellular β-catenin
induces nuclear localization of β-catenin in DD cells is yet to be explored. It is currently
unclear if TGF-β can induce EMT independently of IGF-II or if synergistic interactions
are required to activate this process. Future studies should address the possibility that
TGF-β and/or IGF-II can induce EMT in a β-catenin-dependent manner and enhance DD
progression. If this is shown to be the case, the palmar epidermis of individuals with DD
may be compromised by the local fibrosis, and therapeutic interventions to EMT in the
palmar epithelium may inhibit DD recurrence.
Interestingly, many of the genes shown to associate with β-catenin in DD and PF cells
have established roles in cells of neuronal origin (See Appendices F and G). The neural
crest has been hypothesized as a source of mesenchymal stem cells (MSCs) [29], and
increased numbers of MSCs have been reported in DD relative to controls [30,31]. These
cells were postulated to have been derived from both perinodular fat and disease cord
tissues in DD patients and were not evident in palmar fascia samples derived from
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Figure 5-1: Origin of myofibroblasts.
Myofibroblasts can potentially be derived from many sources,
including resident fibroblasts, hepatic stellate cells (HSCs), smooth
muscle cells (SMCs), epithelium or endothelium (through epithelialor endothelial- mesenchymal transition (EMT), or from the bone
marrow, or from stem cells. (Reprinted with permission from Hinz et
al. [32]). The source(s) of the myofibroblasts that induce finger
contractures in DD are yet to be determined.
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patients undergoing carpal tunnel surgeries [30]. Unfortunately, it is unclear if this
increase in MSC numbers in DD tissues was truly associated with DD development or
simply a consequence of a wound healing event in the palmar fascia that was not evident
in the unwounded palmar fascia used as controls. Increased numbers of MSCs are a
normal finding during the repair of many tissues [33–35]. Another possibility is that DD
cells are derived from pericytes, a type of perivascular cell that is derived from the neural
crest, exhibit neural epitopes including NG2, are α-SMA-positive and are highly
contractile [36,37]. Future studies should include the analyses of DD cells for NG2 and
other neural crest markers to confirm the origins of these cells.

5.4

Is IGFBP6 a “fibrosis suppressor gene”?

The findings reported in Chapter 3 demonstrated that IGFBP-6 can inhibit basal
proliferation and IGF-II induced contraction of DD cells. As IGFBP6 expression and
IGFBP-6 secretion are attenuated in DD, this molecule could represent a “fibrosis
suppressor” that is turned off by the loss of β-catenin interactions during DD
development. Thus, re-expression of IGFBP6 in DD cells to the levels evident in CT cells
may drive palmar fascia fibroblasts towards conditions approaching normal homeostasis
where fibrosis is inhibited.
Bexarotene (trade name Targretin, LGD1069) is a retinoid X receptor agonist (rexinoid)
that has been shown to increase IGFBP-6 levels in other systems [38]. This therapeutic
intervention may potentially inhibit connective tissue fibroses including DD. Bexarotene
is an FDA approved cutaneous T cell lymphoma treatment [39] that is currently being
assessed for its efficacy against other cancers [40,41] and neurological diseases [42,43].
Previous studies in breast cancer indicate that the enhanced expression and secretion of
IGFBP-6 is a primary mechanism by which bexarotene inhibits breast cancer cell growth
through an AP-1/c-fos/c-jus-mediated mechanism [38,44]. Additionally, bexarotene has
been shown to repress CCND1 [45], encoding the proliferation-associated cell-cycle
protein cyclin D1, and to inhibit cyclooxygenase-2 (COX-2) [44], which is reported to
increase stromal fibrosis in colorectal cancer [46]. COX-2 inhibitors have been shown to
reduce fibrosis in other systems [47]. It is plausible that bexarotene would increase
IGFBP-6 secretion in fibroblasts and repress CCND1 to limit fibroproliferation in DD.
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Figure 5-2: TGF-β1 treatment of PF and DD cells represses A) IGFBP6
expression and B) IGFBP-6 secretion.
PF and DD cells were treated with TGF-β1 (12.5 ng/ml) for 48 hours. RNA
was extracted and reverse transcribed for analysis by real-time PCR for
IGFBP6 expression. Media was collected and assessed by Luminex
Multiplex assay for IGFBP-6 protein levels. TGF-β1 further repressed both
mRNA and protein levels relative to vehicle treated cells.
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Enhanced IGFBP-6 levels would also be predicted to inhibit IGF-II signalling, thereby
attenuating IGF-II induced myofibroblast contractility. While outside of the main scope
of this thesis, pilot studies were performed to assess the effects of bexarotene treatment of
DD cells in vitro. The preliminary findings indicate that treatment with 1 µM bexarotene
induces IGFBP6 expression by approximately 2-fold and inhibits the proliferation of DD
fibroblasts by approximately 30% over 7 days without affecting PF cell proliferation
(data not shown). These preliminary findings support the hypothesis that bexarotene may
have utility as an inducer of endogenous IGFBP6 expression and inhibitor of
fibroproliferation in DD, and these studies are ongoing in our laboratory.

5.5

Mechanisms of IGF-II induced contraction

A novel role for IGF-II as an inducer of DD myofibroblast contractility was identified in
Chapter 3. Intriguingly, IGF-II induced contraction of DD and PF cells without inducing
any significant effects on α-smooth muscle actin (α-SMA) expression or levels,
suggesting that this increased contractility was independent of the differentiation state of
these cells. In addition, IGF-II was shown to induce the ability of DD cells to contract
unstressed collagen lattices. This effect was interpreted as likely to be due to an increase
in three-dimensional migration within the collagen lattice based on the similarities
between the effects of IGF-II and platelet derived growth factor (PDGF), shown to induce
migration in these lattices in previous studies [48,49]. While the signalling pathways
induced by IGF-II to elicit these effects are yet to be elucidated, an intriguing possibility
is that they are mediated through the activation of focal adhesion kinase (FAK). FAK
activation is an established component of integrin signalling and cell migration (reviewed
in [50,51]). Links between ligand-induced activation of the IGFIR and FAK activity
have been reported in cancer cell models [52]. These studies reported IGF-I induced
migration of breast cancer cells through RACK1 (receptor for activated C kinases), a
scaffold protein which links the IGF and integrin pathways [53,54]. IGF-I signalling
through the IGFIR can recruit RACK1 to induce an association with the β1 integrin
subunit through FAK to facilitate cell migration [53]. It is currently unclear if IGF-II
signalling can induce similar effects through the IGFIR, and this should be a priority for
future studies.

127

In addition to its effects on DD migration in three dimensional collagen matrices, pilot
studies beyond the scope of this thesis have provided preliminary evidence that IGF-II
can induce the expression of CDH11, encoding OB-cadherin, in stressed FPCLs.
Increases in CDH11 expression and OB-cadherin levels have been correlated with
increased myofibroblast contractility in previous studies [55]. The inclusion of OBcadherin in adherens junctions has been shown to enhance myofibroblast contractility by
increasing the strength of cell-cell contacts [55], and this may suggest an additional
potential mechanism by which IGF-II might be inducing these effects. Interestingly, βcatenin has been shown to interact with the 3’ untranslated region (UTR) of CDH11 to
stabilize CDH11 expression [56]. Future studies would be required to determine if this βcatenin associates with CDH11 in DD and if IGF-II can induce CDH11 expression in a βcatenin-dependent manner.

5.6
Toward novel therapeutic interventions in
Dupuytren’s Disease
In contrast to its well-established roles in fetal and tumour development, very little is
known about IGF-II in the context of fibrosis. IGF-II signalling has been shown to induce
collagen expression in systemic sclerosis-associated pulmonary fibrosis [57] and future
studies should focus on determining if IGF-II plays a similar role during DD
development. Excessive collagen induction is a hallmark of DD, as it is of most other
fibroproliferative disorders [58–60]. While the findings reported in this thesis support
distinct roles for IGF-II in promoting fibroblast migration and myofibroblast contraction
in DD, it is important that future studies assess the combinatorial roles of IGF-II with
other growth factors and cytokines that contribute to the DD microenvironment. The
suppression of IGF-II signalling may help to ameliorate DD severity or recurrence, but it
is unlikely that inhibition of IGF-II signalling in isolation will be sufficient. Therapeutic
interventions that increase endogenous IGFBP-6 levels, such as bexarotene, may inhibit
fibro-proliferation through IGF-II dependent and IGF-II independent mechanisms and be
more effective than targeting IGF-II alone. However, the most effective therapeutic
approach may be to inhibit fibroproliferation by attenuating β-catenin-mediated transregulation of gene transcription in DD.
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Resveratrol (3,4’,5-trihydroxystilbene) is a natural phytoalexin which has been
demonstrated to decrease survival of colorectal cancer and Wnt-stimulated cells. Its
mechanism of action appears to be dependent on inhibiting β-catenin interaction with
TCF3, thereby suppressing the expression of c-Myc, Axin2 and cyclin D1 and potentially
other targets of the Wnt signalling pathway [61]. Additionally, Nefopam (5-methyl-1phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine) has recently been identified as having
utility in reducing β-catenin levels in aggressive fibromatosis. This drug can inhibit
proliferation of fibroblasts derived from aggressive fibromatosis and hypertrophic scars
without discernible effects on control cells, and has been shown to reduce scar size in
vivo [62]. It may be possible to combine multiple treatments to target both the IGF-II and
β-catenin signalling pathways in Dupuytren’s Disease to inhibit disease progression
and/or recurrence. It is hoped that the findings presented in this thesis will provide an
incremental advance in our knowledge of the pathophysiology of DD and facilitate the
development of more effective therapeutic interventions for these patients.
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Appendix C: Western University Research Ethics Board for Health Sciences
Research involving Human Subjects (HSREB protocol # 08222E)
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Appendix D: PERL script used to process raw ChIP Seq data and align to genome
for d in $( ls ./ | grep _lib ); do
echo $d
mkdir md5
mv $d/*.md5 md5/
for f in $( ls $d/ | grep -v md5 | grep fastq ); do
echo $d/$f
gunzip $d/$f
done
done
for f in $( ls ./ | grep fastq ); do
echo $f
cat $f >> $SAMPLE.all.fastq
echo "removing $f"
rm $f
done
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Appendix E: PERL Script used to map common peaks back to human genome
#!/usr/bin/env perl -w
use strict;
#open the sorted bed file and create an array
#of positions for a chromosome (specified on the command line)
#containing accesssion numbers
#ARGV[0] is sorted bed file
#ARGV[1] is the chromosome
#ARGV[2] is the filtered file
print "to run:\n./merge_tabular_bed_efficient.pl
../Downloads/Galaxy47-\[Sorted_RefSeq_Upstream_50kb\].bed
../Downloads/Galaxy147-\[Filter_on_data_145\].tabular chr1 >
test_chr1.txt \n" if ! $ARGV[0];
exit if ! $ARGV[0];
#print out accession for start and stop positions in filtered
file
my @start = my @stop; my %id;
open (IN, "< $ARGV[0]") or die;
while(my $l = <IN>){
my @l = split/\t/, $l;
chomp $l;
if ($l[0] eq$ARGV[2]){
push @start, $l[1];
push @stop, $l[2];
my @nm = split/_/, $l[3];
$id{$l[1]} = $nm[0] . "_$nm[1]";
}
}
close IN;
my %seen;
open (IN, "< $ARGV[1]") or die;
while(my $l = <IN>){
chomp $l;
my @l = split/\t/, $l;
if ($l[0] eq $ARGV[2]){
for (my $i=0; $i < @start; $i++){
if ($l[1] >= $start[$i] && $l[2] <=
$stop[$i]){
print "$id{$start[$i]}\n" if !defined
$seen{$start[$i]};
$seen{$start[$i]} = "";
}
}
}
}
close IN;
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Appendix F: Select β-catenin associations within intronic regions of a gene in PF
cells, but not corresponding DD cells
RefSeq
Accession
Number

Gene
Symbol

Gene Description

Chromosomal
Location

NC_000005.10

ADAMTS
19

ADAM metallopeptidase with thrombospondin type 1
motif, 19

5q23.3

NC_000012.12

ADAMTS
20

ADAM metallopeptidase with thrombospondin type 1
motif, 20

12q12

NC_000007.14

ADCY1

adenylate cyclase 1 (brain)

7p13-p12

NC_000008.11

ADCY8

adenylate cyclase 8 (brain)

8q24

NC_000005.10

AFAP1L1

actin filament associated protein 1-like 1

5q32

NC_000015.10

APBA2

amyloid beta (A4) precursor protein-binding, family A,
member 2

15q11-q12

NC_000004.12

APBB2

amyloid beta (A4) precursor protein-binding, family B,
member 2

4p13

NC_000004.12

ARHGEF3
8

Rho guanine nucleotide exchange factor (GEF) 38

4q24

NC_000010.11

ARMC3

armadillo repeat containing 3

10p12.31

NC_000002.12

BMP10

bone morphogenetic protein 10

2p13.3

NC_000020.11

BMP7

bone morphogenetic protein 7

20q13

NC_000009.12

CACNA1
B

calcium channel, voltage-dependent, N type, alpha 1B
subunit

9q34

NC_000003.12

CACNA1
D

calcium channel, voltage-dependent, L type, alpha 1D
subunit

3p14.3

NC_000003.12

CADM2

cell adhesion molecule 2

3p12.1

NC_000012.12

CD163L1

CD163 molecule-like 1

12p13.3

NC_000001.11

CD247

CD247 molecule

1q24.2

NC_000001.11

CD48

CD48 molecule

1q21.3-q22

NC_000005.10

CDH12

cadherin 12, type 2 (N-cadherin 2)

5p14.3

NC_000016.10

CDH13

cadherin 13

16q23.3

NC_000020.11

CDH4

cadherin 4, type 1, R-cadherin (retinal)

20q13.3
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NC_000003.12

CNTN4

contactin 4

3p26.3

NC_000011.10

CNTN5

contactin 5

11q22.1

NC_000006.12

COL19A1

collagen, type XIX, alpha 1

6q12-q13

NC_000007.14

COL26A1

collagen, type XXVI, alpha 1

7q22.1

NC_000002.12

CTNNA2

catenin (cadherin-associated protein), alpha 2

2p12-p11.1

NC_000010.11

CTNNA3

catenin (cadherin-associated protein), alpha 3

10q22.2

NC_000007.14

EGFR

epidermal growth factor receptor

7p12

NC_000022.11

FAM19A5

family with sequence similarity 19 (chemokine (C-C
motif)-like), member A5

22q13.32

NC_000009.12

FAM219A

family with sequence similarity 219, member A

9p13.3

NC_000013.11

FGF14

fibroblast growth factor 14

13q34

NC_000007.14

FOXP2

forkhead box P2

7q31

NC_000002.12

GPR155

G protein-coupled receptor 155

2q31.1

NC_000007.14

GPR37

G protein-coupled receptor 37 (endothelin receptor
type B-like)

7q31

NC_000011.10

GRIK4

glutamate receptor, ionotropic, kainate 4

11q22.3

NC_000012.12

GRIP1

glutamate receptor interacting protein 1

12q14.3

NC_000006.12

GRM1

glutamate receptor, metabotropic 1

6q24

NC_000001.11

HHAT

hedgehog acyltransferase

1q32

NC_000009.12

JAK2

Janus kinase 2

9p24

NC_000018.10

LAMA3

laminin, alpha 3

18q11.2

NC_000011.10

METTL15

methyltransferase like 15

11p14.1

NC_000016.10

MIR36802

microRNA 3680-2

NC_000023.11

MIR548F5

microRNA 548f-5

Xp21.1

NC_000015.10

MYO1E

myosin IE

15q21-q22

NC_000002.12

MYO3B

myosin IIIB

2q31.1-q31.2

NC_000010.11

PCDH15

protocadherin-related 15

10q21.1

NC_000005.10

PCDHA1

protocadherin alpha 1

5q31
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NC_000005.10

PCDHA10

protocadherin alpha 10

5q31

NC_000005.10

PCDHA11

protocadherin alpha 11

5q31

NC_000005.10

PCDHA12

protocadherin alpha 12

5q31

NC_000005.10

PCDHA13

protocadherin alpha 13

5q31

NC_000005.10

PCDHA2

protocadherin alpha 2

5q31

NC_000005.10

PCDHA3

protocadherin alpha 3

5q31

NC_000005.10

PCDHA4

protocadherin alpha 4

5q31

NC_000005.10

PCDHA5

protocadherin alpha 5

5q31

NC_000005.10

PCDHA6

protocadherin alpha 6

5q31

NC_000005.10

PCDHA7

protocadherin alpha 7

5q31

NC_000005.10

PCDHA8

protocadherin alpha 8

5q31

NC_000005.10

PCDHA9

protocadherin alpha 9

5q31

NC_000006.12

PKIB

protein kinase (cAMP-dependent, catalytic) inhibitor
beta

6q22.31

NC_000006.12

PLG

plasminogen

6q26

NC_000007.14

RELN

reelin

7q22

NC_000009.12

SLC24A2

solute carrier family 24 (sodium/potassium/calcium
exchanger), member 2

9p22.1

NC_000002.12

SLC25A12

solute carrier family 25 (aspartate/glutamate carrier),
member 12

2q24

NC_000008.11

SLC30A8

solute carrier family 30 (zinc transporter), member 8

8q24.11

NC_000002.12

SP3

Sp3 transcription factor

2q31

NC_000019.10

ZNF431

zinc finger protein 431

19p12

NC_000007.14

ZNF716

zinc finger protein 716

7p11.2

NC_000007.14

ZNF804B

zinc finger protein 804B

7q21.13
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Appendix G: Select β-catenin associations within intronic regions of a gene in DD
cells, but not corresponding PF cells
RefSeq
Accession
Number

Gene
Symbol

Gene Description

NC_000008.11

ADAM18

ADAM metallopeptidase domain 18

8p11.22

NC_000008.11

ADAM2

ADAM metallopeptidase domain 2

8p11.2

NC_000007.14

ADAM22

ADAM metallopeptidase domain 22

7q21

NC_000002.12

ADAM23

ADAM metallopeptidase domain 23

2q33

NC_000008.11

ADAM28

ADAM metallopeptidase domain 28

8p21.2

NC_000004.12

ADAM29

ADAM metallopeptidase domain 29

4q34

NC_000008.11

ADAM32

ADAM metallopeptidase domain 32

8p11.22

NC_000008.11

ADAM5

ADAM metallopeptidase domain 5, pseudogene

8p11.22

NC_000005.10

ADAMTS
16

ADAM metallopeptidase with thrombospondin type 1
motif, 16

5p15

NC_000016.10

ADAMTS
18

ADAM metallopeptidase with thrombospondin type 1
motif, 18

16q23

NC_000005.10

ADAMTS
19

ADAM metallopeptidase with thrombospondin type 1
motif, 19

5q23.3

NC_000007.14

ADCY1

adenylate cyclase 1 (brain)

7p13-p12

NC_000005.10

ADCY2

adenylate cyclase 2 (brain)

5p15.3

NC_000002.12

ADD2

adducin 2 (beta)

2p13.3

NC_000008.11

ADRA1A

adrenoceptor alpha 1A

8p21.2

NC_000002.12

ALK

anaplastic lymphoma receptor tyrosine kinase

2p23

NC_000015.10

APBA2

amyloid beta (A4) precursor protein-binding, family A,
member 2

15q11-q12

NC_000018.10

APCDD1

adenomatosis polyposis coli down-regulated 1

18p11.22

NC_000002.12

ARHGEF4

Rho guanine nucleotide exchange factor (GEF) 4

2q22

NC_000010.11

ARMC3

armadillo repeat containing 3

10p12.31

NC_000010.11

ARMC4

armadillo repeat containing 4

10p12.1-p11.23

Chromosomal
Location
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NC_000006.12

BAI3

brain-specific angiogenesis inhibitor 3

6q12

NC_000020.11

BMP7

bone morphogenetic protein 7

20q13

NC_000001.11

BRINP3

bone morphogenetic protein/retinoic acid inducible
neural-specific 3

1q31.1

NC_000003.12

CADM2

cell adhesion molecule 2

3p12.1

NC_000018.10

CCDC102
B

coiled-coil domain containing 102B

18q22.1

NC_000018.10

CCDC11

coiled-coil domain containing 11

18q21.1

NC_000001.11

CD244

CD244 molecule, natural killer cell receptor 2B4

1q23.3

NC_000001.11

CD247

CD247 molecule

1q24.2

NC_000002.12

CD302

CD302 molecule

2q24.2

NC_000011.10

CD3E

CD3e molecule, epsilon (CD3-TCR complex)

11q23

NC_000003.12

CD86

CD86 molecule

3q21

NC_000003.12

CD96

CD96 molecule

3q13.13-q13.2

NC_000005.10

CDH12

cadherin 12, type 2 (N-cadherin 2)

5p14.3

NC_000016.10

CDH13

cadherin 13

16q23.3

NC_000005.10

CDH18

cadherin 18, type 2

5p14.3

NC_000018.10

CDH19

cadherin 19, type 2

18q22.1

NC_000020.11

CDH4

cadherin 4, type 1, R-cadherin (retinal)

20q13.3

NC_000018.10

CDH7

cadherin 7, type 2

18q22.1

NC_000016.10

CDH8

cadherin 8, type 2

16q22.1

NC_000013.11

CDK8

cyclin-dependent kinase 8

13q12

NC_000001.11

CHRM3

cholinergic receptor, muscarinic 3

1q43

NC_000015.10

CHRNA7

cholinergic receptor, nicotinic, alpha 7 (neuronal)

15q14

NC_000006.12

COL19A1

collagen, type XIX, alpha 1

6q12-q13

NC_000008.11

COL22A1

collagen, type XXII, alpha 1

8q24.3

NC_000005.10

COL23A1

collagen, type XXIII, alpha 1

5q35.3

NC_000007.14

COL28A1

collagen, type XXVIII, alpha 1

7p21.3
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NC_000002.12

COL4A4

collagen, type IV, alpha 4

2q35-q37

NC_000003.12

COL6A5

collagen, type VI, alpha 5

3q22.1

NC_000006.12

COL9A1

collagen, type IX, alpha 1

6q13

NC_000002.12

CTNNA2

catenin (cadherin-associated protein), alpha 2

2p12-p11.1

NC_000010.11

CTNNA3

catenin (cadherin-associated protein), alpha 3

10q22.2

NC_000005.10

CTNND2

catenin (cadherin-associated protein), delta 2

5p15.2

NC_000011.10

DRD2

dopamine receptor D2

11q23

NC_000014.9

ESRRB

estrogen-related receptor beta

14q24.3

NC_000001.11

ESRRG

estrogen-related receptor gamma

1q41

NC_000015.10

FAM189A
1

family with sequence similarity 189, member A1

15q13.1

NC_000003.12

FAM19A1

family with sequence similarity 19 (chemokine (C-C
motif)-like), member A1

3p14.1

NC_000003.12

FGF12

fibroblast growth factor 12

3q28

NC_000013.11

FGF14

fibroblast growth factor 14

13q34

NC_000004.12

GABRA2

gamma-aminobutyric acid (GABA) A receptor, alpha 2

4p12

NC_000015.10

GABRA5

gamma-aminobutyric acid (GABA) A receptor, alpha 5

15q12

NC_000004.12

GABRB1

gamma-aminobutyric acid (GABA) A receptor, beta 1

4p12

NC_000001.11

GBP7

guanylate binding protein 7

1p22.2

NC_000005.10

GHR

growth hormone receptor

5p13-p12

NC_000010.11

GPR158

G protein-coupled receptor 158

10p12.1

NC_000005.10

GPR98

G protein-coupled receptor 98

5q13

NC_000011.10

GRIA4

glutamate receptor, ionotropic, AMPA 4

11q22

NC_000010.11

GRID1

glutamate receptor, ionotropic, delta 1

10q22

NC_000011.10

GRIK4

glutamate receptor, ionotropic, kainate 4

11q22.3

NC_000016.10

GRIN2A

glutamate receptor, ionotropic, N-methyl D-aspartate
2A

16p13.2

NC_000001.11

HHAT

hedgehog acyltransferase

1q32

NC_000004.12

HHIP

hedgehog interacting protein

4q28-q32
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NC_000004.12

IL15

interleukin 15

4q31

NC_000001.11

IL23R

interleukin 23 receptor

1p31.3

NC_000002.12

IL36B

interleukin 36, beta

2q14

NC_000002.12

ITGA4

integrin, alpha 4 (antigen CD49D, alpha 4 subunit of
VLA-4 receptor)

2q31.3

NC_000016.10

ITGAD

integrin, alpha D

16p11.2

NC_000009.12

KGFLP2

keratinocyte growth factor-like protein 2

9p12

NC_000006.12

LPA

lipoprotein, Lp(a)

6q26

NC_000001.11

LRRC52

leucine rich repeat containing 52

1q24.1

NC_000014.9

LRRC74

leucine rich repeat containing 74

14q24.3

NC_000017.11

MAP2K4

mitogen-activated protein kinase kinase 4

17p12

NC_000015.10

MAP2K5

mitogen-activated protein kinase kinase 5

15q23

NC_000017.11

MAP2K6

mitogen-activated protein kinase kinase 6

17q24.3

NC_000019.10

MBD3L2

methyl-CpG binding domain protein 3-like 2

19p13.2

NC_000012.12

METTL25

methyltransferase like 25

12q21.31

NC_000010.11

MGMT

O-6-methylguanine-DNA methyltransferase

10q26

NC_000023.11

MIR548I4

microRNA 548i-4

Xq21.1

NC_000007.14

MIR548N

microRNA 548n

7p14.3

NC_000004.12

MIR548T

microRNA 548t

NC_000016.10

MIR548W

microRNA 548w

NC_000007.14

MIR5692
A1

microRNA 5692a-1

NC_000014.9

MIR5694

microRNA 5694

NC_000006.12

MYLK4

myosin light chain kinase family, member 4

6p25.2

NC_000013.11

MYO16

myosin XVI

13q33.3

NC_000022.11

MYO18B

myosin XVIIIB

22q12.1

NC_000010.11

MYO3A

myosin IIIA

10p11.1

NC_000011.10

NCAM1

neural cell adhesion molecule 1

11q23.1
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NC_000021.9

NCAM2

neural cell adhesion molecule 2

21q21.1

NC_000001.11

NEGR1

neuronal growth regulator 1

1p31.1

NC_000008.11

NRG1

neuregulin 1

8p12

NC_000010.11

NRG3

neuregulin 3

10q22-q23

NC_000020.11

PAK7

p21 protein (Cdc42/Rac)-activated kinase 7

20p12

NC_000010.11

PCDH15

protocadherin-related 15

10q21.1

NC_000013.11

PCDH9

protocadherin 9

13q21.32

NC_000016.10

PRKCB

protein kinase C, beta

16p11.2

NC_000001.11

PTGER3

prostaglandin E receptor 3 (subtype EP3)

1p31.2

NC_000002.12

RAPGEF4

Rap guanine nucleotide exchange factor (GEF) 4

2q31-q32

NC_000007.14

RAPGEF5

Rap guanine nucleotide exchange factor (GEF) 5

7p15.3

NC_000007.14

RELN

reelin

7q22

NC_000020.11

SLC24A3

solute carrier family 24 (sodium/potassium/calcium
exchanger), member 3

20p13

NC_000014.9

SLC25A21

solute carrier family 25 (mitochondrial oxoadipate
carrier), member 21

14q11.2

NC_000003.12

SLC25A26

solute carrier family 25 (S-adenosylmethionine
carrier), member 26

3p14.1

NC_000012.12

SLC2A13

solute carrier family 2 (facilitated glucose transporter),
member 13

12q12

NC_000004.12

SLC2A9

solute carrier family 2 (facilitated glucose transporter),
member 9

4p16.1

NC_000008.11

SLC30A8

solute carrier family 30 (zinc transporter), member 8

8q24.11

NC_000013.11

SMAD9

SMAD family member 9

13q12-q14

NC_000012.12

SOX5

SRY (sex determining region Y)-box 5

12p12.1

NC_000007.14

SP4

Sp4 transcription factor

7p15.3

NC_000011.10

SPON1

spondin 1, extracellular matrix protein

11p15.2

NC_000006.12

TFAP2B

transcription factor AP-2 beta (activating enhancer
binding protein 2 beta)

6p12

NC_000002.12

TFCP2L1

transcription factor CP2-like 1

2q14
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NC_000002.12

TGFA

transforming growth factor, alpha

2p13

NC_000001.11

TNFSF4

tumor necrosis factor (ligand) superfamily, member 4

1q25

NC_000001.11

WLS

wntless Wnt ligand secretion mediator

1p31.3

NC_000008.11

ZFAT

zinc finger and AT hook domain containing

8q24.22

NC_000008.11

ZMAT4

zinc finger, matrin-type 4

8p11.21

NC_000007.14

ZNF277

zinc finger protein 277

7q31.1

NC_000019.10

ZNF28

zinc finger protein 28

19q13.41
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Appendix H: Creative Commons License allowing Raykha et al. 2013 to be
reprinted without permission (Open Access article)
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Appendix I: License to use figure from Hinz et al. 2007.
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